initi coverag
initi ow pt
invest summari initi coverag merck co ow
rate pt sale growth across oncolog vaccin anim
health select hospital/specialti care product well margin expans
opportun underappreci view therefor expect upward
earn revis multipl expans drive share higher
still see upsid consensu estim keytruda sale keytruda
could view factset still earli
develop keytruda first truli broad-spectrum antineoplast agent
indic come mani indic yet
broaden world-wide keytruda monotherapi studi larg complet
believ merck continu execut strategi explor
combin studi simultan advanc salvag therapi
set adjuv neoadjuv set across variou
tumor type view continu leadership key area nsclc addit
opportun rcc tnbc head neck gastric tumor type
intern opportun big growth driver keytruda
 upsid opportun keytruda turn cold tumor hot
hemispherx biopharma cover chines market
subcutan dose keytruda start could extend
keytruda patent life keytruda margin could improv
cover royalti step start six-week dose
melanoma could make keytruda competit
 drug pipelin outsid keytruda underappreci oncolog
lynparza lenvima oncolog asset uniqu mechan
vaccin gardasil pneumococc rsv cmv dengu area
hospit zerbaxa bridion gefapix phase
studi chronic cough novel asset hiv neurosci expect
hear product new one investor day june
 oper margin expans increas earn potenti
expect meaning operating-margin expans long term near term
expect spend outpac sale growth sg manag
tightli oper leverag driven oper expens
moder versu sale especi
disclosur section may found page
major
initi coverag merck co inc
tabl content
snapshot valuat risk
catalyst
keytruda head
keytruda combin
lynparza
definit abbrevi tabl content
compani descript merck global compani whose core
product categori includ cancer diabet vaccin
gardasil bridion anim health merck reach
sale merck incorpor new jersey
invest summari initi coverag
stock ow rate pt sale
growth across oncolog vaccin anim health select
hospital/specialti care product well margin-expans
opportun underappreci view therefor
expect upward earn revis multipl expans
drive mrk share higher
upsid factset consensu estim keytruda
drug pipelin outsid keytruda still appear
competit setback key product
 effort may unsuccess
price pressur respect product
import posit catalyst stock
data tnbc
incom ep consensusbrok rate price merck compani overview timelin recent event
exhibit compani overview timelin recent event
merger merck co
schering-plough continu
surviv public compani
renam merck co
june termin merck
relationship astrazeneca lp azlp
august complet acquisit
cash
septemb keytruda approv
fda becom first
therapi approv
octob complet sale merck
consum busi bayer ag
world-wide
collabor bayer market
develop novel therapi cv diseas
therapeut indic
januari complet acquisit
consider
februari enter multi-year
collabor privat held
biopharmaceut compani focus
discoveri develop novel cancer
juli enter agreement
allergan merck investig small
peptid cgrp receptor antagonist
treatment prevent migrain
vall
privat held produc anim
health product brazil
juli enter global
strateg oncolog collabor
astrazeneca co-develop co-
lynparza multipl cancer type
well astrazeneca selumetinib
restructur program part
global
sharpen commerci
decemb fda approv
acquisit oncoethix
evalu
respect role anim health
consum busi merck
determin
anim health
merck
presid elect cep
drug discoveri compani focus
develop innov medicin
treatment cancer particular
immunotherapi cancer metabol
up-front mileston payment
licens agreement
collabor
develop
total consider
march enter strateg
collabor eisai co ltd
world-wide co-develop
co-commerci lenvima
limit australian publicli trade
focus oncolyt
rang cancer aud
design
exhibit merck bull bear base case analysi
arriv price target
merck share use blend
dcf ev/ebitda bull bear
dcf analysi arriv
month share price
assum wacc exit
multipl higher
ev/ebit multipl merck
peer averag think
deserv given merck
leadership io exhibit
next page
equiti
ev/ebitda analysi arriv
ev/ebitda multipl higher
compar averag
think
deserv given
merck leadership io
bull bear base case analys
forecast likelihood
stock worth
next month pleas see
exhibit right detail
cantor fitzgerald research compani reportsbul casekeytrudapeak sale vaccin sale exceed expectationsoper margin expans exce expectationsnew pipelin opportun exceed scenario casekeytrudapeak sale vaccin sale line expectationsoper margin expans line expectationsnew pipelin opportun line scenario casekeytrudapeak sale vaccin sale expectationsoper margin expans expectationsnew pipelin opportun scenario merck equiti compani compar
cover cantor factset
tickercompanypric cap mm debt/ ev/ ev/ price/ yield yield ep gr djiidow jone industri vector large-cap pharmabmybristol myer specialti large-cap cap mm debt/ ev/ ev/ price/ yield yield ep gr ratepeg ratio jone industri vector large-cap pharmabmybristol myer specialti pharmaceut ag chf large-cap device/hospit supplyabtabbott factset cantor fitzgerald estim factset compani coverag mark ep estim adjust non-oper item debt/ebitda estim ebitda arithmet chang stock price februari
competit setback key product could materi neg impact
merck abil gener profit oper cash flow depend larg continu profit compani key product
januvia janumet keytruda gardasil/gardasil isentress result compani depend key product event
advers affect product market product could signific advers impact result oper
cash flow event could includ loss patent protect increas cost associ manufactur gener over-the-count
avail compani product competit product discoveri previous unknown side effect result post-approv trial
increas competit introduct new more-effect treatment discontinu remov market product
reason event could materi advers effect sale product
merck effort may succeed develop commerci success product
like major pharmaceut compani order remain competit merck must continu launch new product year expect
declin sale product loss market exclus mean compani futur success depend pipelin new
product includ new product may develop collabor joint ventur product abl obtain
licens acquisit accomplish compani commit substanti effort fund resourc research develop
dedic resourc variou collabor third parti high rate failur inher research
develop process new drug result high risk fund invest merck research program gener
financi return risk profil compound fact research long invest cycl bring pharmaceut compound
discoveri phase market may take decad failur occur point process includ later process
signific fund invest
merck could continu face price pressur respect product
merck could continu face price pressur global particularli matur market manag care organ govern
agenc program could neg affect compani sale profit margin unit state includ practic
manag care group institut government purchas feder law regul relat medicar medicaid
includ medicar prescript drug improv modern act state activ aim increas
price transpar chang healthcar system enact part healthcar reform unit state well increas purchas
power entiti negoti behalf medicar medicaid privat sector beneficiari could result price pressur
addit larger custom may futur ask receiv higher rebat drug certain highli competit categori
compani must also compet place formulari manag care organ exclus product formulari lead
reduc usag manag care organ
merck compani report cantor fitzgerald research
expect upsid factset estim keytruda
still earli develop keytruda first truli broad-spectrum antineoplast agent
indic come
sale keytruda could view factset
non-smal cell lung cancer nsclc market bolu keytruda data nsclc establish high barrier
competit view even data readout come key competitor opdivo think
keytruda exceed sale
melanoma think keytruda abl take away meaning share opdivo adjuv set follow
recent approv base model split adjuv melanoma
renal cell carcinoma rcc expect approv keytruda inlyta axitinib rcc set although
lowest hang fruit combin like new soc favor risk patient also believ
keytruda inlyta compet opdivo yervoy apples-to-appl basi think
interim data look better data within checkpoint inhibitor
market think keytruda inlyta captur share intermediate/poor risk patient share
favor risk patient
think keytruda monotherapi combin therapi success enter new market tripl neg breast
cancer earlier line treatment head neck cancer
although competitor product trial look interest confid merck leadership posit
posit outcom mani merck studi set bar futur trial read-out space addit
keytruda market four year one largest develop program way
clinic trial studi keytruda combin
follow opportun on-going later-stag trial could potenti expand peak sale potenti
keytruda data readout posit sale financi model street expect trial
modest best
combin trial lynparza and/or lenvima
think potenti combin studi retain keytruda leadership key tumor type explor new tumor
type increas sale lynparza lenvima remain underappreci on-going combin trial includ phase
trial rcc keytruda lenvima phase trial keytruda lynparza
opportun stage nsclc
phase data readout expect primari outcom measur percentag
particip develop grade pneumon percentag particip complet respons cr
partial respons pr trial stage set includ imfinzi phase trial estimate
primari complet date
opportun earlier adjuv melanoma stage ii
estim primari complet date octob posit data could posit keytruda ahead
opdivo therapi option patient well open market larger number patient given much-
better prospect patient earlier stage melanoma five-year surviv rate stage iiia melanoma
think efficacy/tox trade-off difficult checkpoint inhibitor enter stage ii
opportun adjuvant/neoadjuv tnbc
trial look neoadjuv and/or adjuv set
opportun monotherapi and/or chemotherapi combin bladder
phase data expect tecentriq phase trial expect file
tecentriq previous fail phase trial patient previous treat advanc bladder cancer
look tecentriq monotherapi vs chemotherapi
drug pipelin outsid keytruda still appear underappreci
think gardasil abl continu achiev high sale growth exceed think
growth primarili driven launch uptak increas demand market china eu
also believ coverag current level could grow someth closer routin
recommend adolesc vaccin
addit upsid opportun gardisil merck drug pipelin get attent
oncolog lynparza lenvima oncolog asset uniqu mechan
vaccin pneumococc rsv cmv dengu area
gefapix phase studi chronic cough
novel asset hiv neurosci
expect hear product new one investor day june
pleas see appendix detail aforement product
margin expans opportun increas merck earn potenti
near term driven continu top-lin growth key product keytruda gardasil bridion
disciplin sg manag off-set faster-than-sal spend growth
merck get bolu invest next year keytruda lynparza lenvima
vaccin program think sale outpac
expect margin improv gross basi merck royalti bristol cover keytruda sale
fall start
also think merck navig loss exclus key drug still achiev meaning
oper margin expans despit challeng
headwind believ merck success navig
residu pressur zetia eu loe april vytorin eu loe gener challeng launch ahead
april patent protect cancida invanz gener entri
upcom loe headwind noxafil loe juli eu loe decemb nuvar gener entri
expect emend loe septemb eu loe februari
eu biosimilar pressur simponi remicad eu pressur humira biosimilar entri octob
expect continu simponi due overlap indic greater expect pressur remicad due
direct biosimilar competit
neg impact expand medicar part donut hole expect increment impact sale
januvia
gener competit januvia/janumet start
esophag file regulatori author
sclc earlier potenti interim data
ph trial combin
merck press releas clinicaltri gov
merck detail catalyst event
exhibit catalyst event calendar
merck compani report clinicaltri gov cantor fitzgerald research
datedriverupcom estimate primari complet unresect biliari tract cancer april estimate primari complet hiv infect combin date first-lin nsclc june date habp/vabp pneumonia june date hnscc june date small cell lung cancer june eventjun date first-lin renal cell carcinoma june pneumoconjug vaccin phase estimate primari anim healthclos antelliq group designclos doravirin approv decis second-lin metastat breast polo data germlin brca mutat first-lin pancreat juli imipenem/cilastatin imi/rel pdufa date cuti ciai juli patent expirationaugust aqu patent expir formul septemb injectionu patent expir septemb cv outcom studi estimate primari completionseptemb delstrigopdufa date octob primari complet date endometriosi decemb pneumoconjug vaccin phase estimate primari data first-lin ovarian combin profound data second-lin metastat castration-resist prostat selumetinib regulatori submiss accept pediatr neurofibromatosi aspect-np data present habp/vabp top-lin announc septemb regulatori author regulatori author chemo combo/mono first-lin head pneumoconjug vaccin phase data studi healthi data first-lin gastric registration-en data non-muscl bladder data second-lin triple-neg breast data first-lin bladder mono/combo data first-lin msi-h colorect data neoadjuvant/adjuv first-lin triple-neg breast data first-lin triple-neg breast registration-en data second-lin cutan squamou cell interim phase data first-lin extens stage small cell lung cancer interim phase data relaps refractori classic hodgkin patent patent patent roll bla submiss ebola vaccin merck detail catalyst event cont
exhibit catalyst event calendar cont
merck compani report clinicaltri gov cantor fitzgerald research
datedriverupcom aqeu patent expir aqjapan patent expir patent estimate primari complet date heart failur januari pneumoconjug vaccin phase estimate primari complet april pneumoconjug vaccin phase estimate primari complet april pneumoconjug vaccin phase estimate primari complet april studi data first-lin renal cell cancer combin may patent expir combin juli stay expir juli estimate primari complet chronic cough august estimate primari complet respiratori synctial viru decemb estimate primari complet metastat castration-resist prostat data second-lin nasopharyng data second-lin nsclc stage data first-lin extens stage small cell lung cancer patent expir injectioneu patent injectionjapan patent patent expir method pediatr hexaval combin vaccin patent expir method pediatr hexaval combin vaccin avail commerci suppli januari estimate primari complet chronic cough januari pneumoconjug vaccin phase estimate primari complet februari pneumoconjug vaccin phase estimate primari complet april propel estimate primari complet mcrpc cytomegaloviru cmv vaccin phase estimate primari patent expir februari estimate primari complet advanc endometri cancer may estimate primari complet advanc non-smal cell lung cancer juli patent expirationjuli patent expirationjuli xru patent patent patent patent patent data relaps refractori classic hodgkin patent patent ebola vaccin patent selumetinib patent expir august estimate primari complet advanc solid patent spc patent spc expir merck detail catalyst event cont
exhibit catalyst event calendar cont
merck compani report clinicaltri gov cantor fitzgerald research
datedriverupcom patent patent patent patent patent spc patent spc patent patent expir patent patent spc patent spc expirationjanuari patent expir pend decemb patent expirationjun patent expir pend septemb patent expir patent expirationfebruari patent expirationapril patent expir pend may patent expir pend june patent expirationjun patent expirationjun patent patent spc patent expirationnovemb patent patent expir pend relebactam imipenem/cilastatin patent patent spc expirationmay patent patent patent expir pend patent expir pend patent expir pend doravirin patent doravirine/lamivudine/tenofovir disoproxil fumar patent patent patent patent expir pend financi model assumpt
merck cantor expect assumpt
summar sale expect merck current product portfolio purpos report
focu merck oncolog vaccin busi two area believ central thesi
detail product found appendix present
exhibit cantor sale expect
merck compani report cantor fitzgerald research
productdescriptioncantor sale expect therapi approv monotherapi combin treatment variou tumor type think keytruda achiev total sale driven key tumor type like nsclc melanoma well new opportun rcc head neck tnbc eu growth driven continu uptak non squamou mnsclc follow septemb approv merck work reimburs process major eu market throughout prevent chemotherapy-induc post-op nausea vomit rapid gener eros begin driven loe eu japan temodarchemotherapi treatment certain type brain tumor continu mid-singl digit sale eros driven intern sale allianc revenu lynparzaor parp inhibitor approv certain type ovarian breast cancer strong/sustain double-digit growth potenti upsid ongoing/futur combin trial keytruda merck/astrazeneca deal lynparza also allow merck jointli develop/commerci astrazeneca selumetinib select mek inhibitor could explor combin studi think potenti combin studi retain keytruda leadership key tumor type explor new tumor type increas sale lynparza remain underappreci allianc revenu lenvimatyrosin kinas inhibitor approv variou tumor type strong/sustain double-digit growth potenti upsid ongoing/futur combin trial keytruda phase trial rcc think potenti combin studi retain keytruda leadership key tumor type explor new tumor type increas sale lenvima remain underappreci oncolog merck cantor expect assumpt cont
exhibit cantor sale expect cont
merck compani report cantor fitzgerald research
productdescriptioncantor sale expect help prevent certain cancer diseas caus certain type human papillomaviru hpv high single-digit sale growth driven primarili launch uptak increas demand market china eu moder growth think coverag level current level could grow someth closer routin recommend adolesc vaccin expect sale growth high mid-singl digit proquad/m-m-r ii/varivaxproquad pediatr combin vaccin help protect measl mump rubella varicella m-m-r ii vaccin help protect measl mump rubella varivax vaccin help prevent chickenpox stabl low- mid-singl digit sale growth pneumovax help prevent pneumococc diseas low- mid-singl digit sale growth rotateqvaccin help protect rotaviru gastroenter infant children stabl low single-digit growth zostavaxvaccin help prevent shingl herp zoster adult year age older continu signific high double-digit sale eros due competitor product glaxosmithklin shingrix receiv preferenti recommend advisori committe immun practic octob addit expect eros ex-u market bridionfor revers two type neuromuscular block agent use surgeri continu double-digit sale growth driven primarili sale gener eros begin eu follow gener eros japan prevent invas fungal infect rapid gener eros begin driven eu loe invanzpenem antibacteri treatment certain infect signific double-digit sale declin driven primarili decreas sale result gener competit cubiciniv antibiot complic skin skin structur infect bacteremia caus design suscept organ mid single-digit sale eros major gener eros taken place antifung certain infect continu double-digit gener eros eu loe addit eros begin japan loe primaxiniv broad-spectrum beta-lactam treatment seriou infect caus design suscept bacteria steadi mid-singl digit sale eros driven primarili ex-u market vaccineshospit acut merck cantor expect assumpt cont
exhibit cantor sale expect cont
merck compani report cantor fitzgerald research
productdescriptioncantor sale expect subcutan treatment certain inflammatori diseas low- mid-singl digit sale eros gener humira remicadetreat inflammatori diseas continu price volum declin result biosimilar competit neurosciencebelsomrafor treatment insomnia low double-digit/high single-digit world-wide sale growth driven primarili growth isentress/isentress hdhiv integras inhibitor use combin antiretrovir agent treatment infect continu sale declin driven continu competit pressur follow gener eros eu/japan start chronic hepat hcv infect signific sale declin due increas competit declin patient volum zetiacholesterol modifi medicin lower ldl-c vytorincholesterol modifi medicin lower ldl-c atozetcholesterol modifi medicin lower ldl-c steadi singl digit growth adempasfor treatment pulmonari arteri hypertens steadi singl digit dipeptidyl inhibitor treatment type diabet digit sale declin impact continu price pressur chang medicar part coverag gap follow rapid gener eros lead inhibitor treatment type diabet digit sale declin impact continu price pressur follow rapid gener eros lead contracept product rapid gener eros begin subderm contracept implant mid-singl digit sale growth prior singulairfor chronic treatment asthma relief symptom allerg rhiniti continu gener eros cozaar/hyzaartreat hypertens continu gener eros nasonexfor treatment nasal allergi symptom continu gener eros arcoxiafor treatment arthriti pain continu gener eros follistim aqus fertil treatment women men continu double-digit sale declin driven lower demand fosamaxfor treatment prevent osteoporosi continu gener eros duleracombin medicin treatment asthma continu competit price pressur follow gener eros anim diversifi brand franchis includ certain product approach expir market exclus longer protect patent develop market mid- high-singl digit growth driven primarili companion anim well livestock cardiovascularimmunologyvirologydiabeteswomen healthdiversifi brand anim healthcontinu double-digit gener eros driven primarili eu japan impact merck estim versu guidanc
fitzgerald million except per share oper expenseslow- mid-singl digit increas effect tax cantor fitzgerald research compani revenu guidanc includ neg impact foreign exchang mid-januari exchang rate non-gaap ep guidanc includ posit impact foreign sale includ replenish dose gardasil borrow cdc vaccin stockpil lost sale due june cyber-attack unfavor affect revenu merck expect gross margin roughli flat yoy believ tailwind includ improv product mix keytruda gardasil bridion gener off-set headwind includ lower price royalti payment fluctuat fx continu amort collabor incom expens expect roughli zero base current market condit invest portfolio merck assum neg impact equiti invest merck also expect higher net interest expens given cash debt balanc given current interest rate market movement could creat addit volatil due invest keytruda lynparza lenvima well vaccin program merck expect grow near-term faster sale next coupl year merck get bolu program slow rate slower sale thereaft sg continu manag tightli merck quarterli incom statement
million except per share amount compound-annual-growth-rate year end decemb gener oper incom attribut share dilut changetot gener incom attribut share dilut cantor fitzgerald research compani report includ exchang loss equiti incom loss affili net period defin benefit plan credit cost servic cost net amount adjust acquisit divestiture-rel cost certain item acquisit divestiture-rel cost expens amort intang asset recogn result acquisit amort purchas account adjust inventori relat acquisit inc intang asset impair charg integr transact certain cost relat busi acquisit includ sever cost part compani formal restructur program well transact certain cost relat busi divestitur in-process research develop ipr impair charg reduct expens result decreas estim fair valu liabil conting consider goodwil impair charg relat certain busi within segment restructur cost primarili includ employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item primarili reflect foreign exchang loss devalu compani net monetari asset venezuela net charg settl vioxx sharehold class action litig gain divestitur certain migrain clinic develop program gain divestitur compani remain ophthalm busi intern market relat tax effect exclud acquisit divestiture-rel cost expens amort intang asset recogn result busi acquisit intang asset impair charg integr transact certain cost relat busi acquisit divestitur ipr impair charg expens relat increas estim fair valu measur liabil conting consider goodwil intang asset impair charg relat busi segment well expens relat chang estim fair valu measur liabil conting consider partial off-set royalti incom connect termin sanofi-pasteur msd joint ventur restructur cost primarili includ employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item includ aggreg charg record conjunct format collabor astrazeneca relat tax effect exclud acquisit divestiture-rel cost amort intang asset recogn result busi acquisit integr transact certain cost relat busi acquisit divestitur ipr impair charg partial off-set reduct expens relat decreas estim fair valu measur liabil conting consider goodwil impair charg relat certain busi segment increas estim fair valu measur liabil conting consider partial off-set royalti incom relat termin sanofi-pasteur msd joint ventur restructur cost employe separ cost acceler depreci associ facil close divest relat activ compani formal restructur program certain item relat tax effect merck margin analysi
cantor fitzgerald research compani report merck quarterli sale
million year end decemb hospit acut immunology- women diversifi total hospit acut women diversifi vericiguat total pipeline- total anim health total anim anim health anim total anim revenu total changeu acut acut anim healthtot anim anim health anim anim cantor fitzgerald research compani report separ belsomra atozet adempa sale atozet market certain countri outsid lead commerci right adempa countri outsid america merck began promot distribut adempa europ merck record sale adempa separ livestock companion anim revenu compris primarili segment revenu third-parti manufactur sale miscellan corpor revenu includ revenu hedg activ merck annual sale
end decemb acut acut pharmaceut pipeline- anim health total anim anim health anim anim revenu cantor fitzgerald research compani report separ belsomra sale belsomra sale includ number belsomra estim separ livestock companion anim number livestock companion anim estim revenu compris primarili segment revenu third-parti manufactur sale miscellan corpor revenu includ revenu hedg activ year end decemb merck
million decemb fiscal oper activitynet incom alloc non-controlling depreci chang oper asset net oper invest activ capit purchas secur proce sale secur acquisit busi net cash disposit busi net cash divested- net invest financ activitiesnet chang short-term payment proce issuanc debt- purchas treasuri dividend paid proce exercis stock net financ effect exchange-r chang cash cash net increas decreas cash cash equival equival sourc cantor fitzgerald research compani report merck balanc sheet
million decemb fiscal assetscash cash short-term account receiv current total current pp cost less accumul intang total liabil sharehold equitycurr liabilitiesloan payabl current portion long-term trade account accru current incom tax dividend total current long-term defer incom non-current total sharehold equitycommon paid-in retain accumul comprehens less treasuri stock total sharehold non-controlling total total liabili sourc cantor fitzgerald research compani report merck summari market model
exhibit summari market model dollar
 summarytreat month summaryu head total treatment gross revenu keytruda net revenu keytruda net revenu keytruda yoy cantor fitzgerald research compani reportsyear end decemb keytruda
keytruda pembrolizumab merck current lead asset futur growth driver purpos
report dive current biggest market
also look addit futur market opportun cite merck includ
head neck cancer
market review follow
current market landscap checkpoint inhibitor
tailwind headwind keytruda sale market
gener physician spoken believ merck keytruda effect
support observ clinic data although direct head-to-head comparison made
mechanist doctor note bind receptor block interact two
ligand releas pathway-medi inhibit immun respons includ anti-tumor immun
respons contrast antibodi bind block ligand interact stop
interact although littl inform avail role cancer immunosuppress
studi suggest presence/abs express may play role
also one look construct antibodi four kind immunoglobulin igg isotyp
keytruda opdivo recent approv libtayo isotyp antibodi tecentriq imfinzi
bavencio isotyp antibodi character gener lower affin fc receptor
complement molecul significantli less potenti antibody-depend cell-medi
cytotox adcc process could detriment activ effector cell physician dont
want erad t-cell
scapin giovanna yang xiaoyu prosis winifr mccoy mark reichert paul johnston jennif kashi ramesh strickland corey structur full-length human therapeut
mahoney freeman mcdermott immune-checkpoint inhibitor blockad melanoma clinic therapeut
puzanov diab abdallah et al manag toxic associ immun checkpoint inhibitor consensu recommend societi immunotherapi cancer toxic manag work group
overview landscap
exhibit major anti anti player
compani report cantor fitzgerald research
compani cover tabl
regeneron sanofi
cover ow rate
productcompanyiniti sale sale sale sale sale sale sale sale sale chf sale sale sale changenananmnmnmnmnmnmu sale sale sale changenmnmnmnmnmnmnmnmu sale sale sale changenmnmnmnmnmnmnmnm collabor merck compani jointli fund develop commerci cost split equal profit gener sell product collabor libtayo cemiplimab sanofi sni septemb nivolumab squibbdecemb atezolizumab roch may durvalumab avelumab march pembrolizumab cantor expect keytruda sale
exhibit keytruda sale forecast dollar
note royalti bristol paid step
exhibit keytruda sale forecast dollar cont
 summarytreat month summaryu head total treatment gross revenu keytruda net revenu keytruda net revenu keytruda yoy cantor fitzgerald research compani reportsyear end decemb million year end decemb keytruda intern total keytruda yoy end decemb keytruda non-smal cell lung cancer nsclc
non-smal cell lung cancer nsclc keytruda import indic given preval nsclc keytruda
current leadership first-lin metastat set expect new case lung cancer
 like nsclc accord seer databas lung cancer distant stage
diagnosi estim incid metastat nsclc estim case
note nation comprehens cancer network nccn guidelin nsclc metastat cancer
spread one site within beyond chest treatment depend type lung cancer biomark
mutat express emerg biomark includ mutat ret gene arrang
high-level amplif exon skip mutat
seer databas nation comprehens cancer network nccn guidelin
current nccn treatment guidelin also cover case biomark absent unknown involv look
histolog type squamou cell carcinoma adenocarcinoma larg cell carcinoma unknown recommend
treatment may also use first-lin treatment metastat lung cancer known biomark
base treatment lung cancer type recommend treatment use depend perform score mainten
treatment type look mainten treatment option well line treatment
perform score rate abil activ measur gener health common score system
ecog eastern cooper oncolog group perform scale
score mean fulli activ
score mean abl self-car activ unabl hard physic work
score mean abl self-car activ spend wake time bed
unabl work
score mean unabl self-car activ work spend wake time
score mean fulli disabl
mainten treatment type look whether stay first-lin treatment mainten
continu chang medicin take first-lin treatment switch go period
test watch chang cancer statu close observation/watch wait
treatment first-lin treatment mainten treatment next-in-lin treatment
nation comprehens cancer network nccn guidelin access detail guidelin found guidelin updat
base current approv due dilig call oncologist believ keytruda monotherapi
combin regimen maintain domin first line mnsclc metastat patient segment
market note keytruda regimen think physician like prescrib
express tp tumor proport score keytruda pemetrex platinum
express tp keytruda pemetrex platinum chemotherapi
express keytruda carboplatin paclitaxel nabpaclitaxel
express tp keytruda carboplatin paclitaxel nabpaclitaxel
express current approv keytruda regimen patient set
mnsclc approv checkpoint inhibitor tecentriq combin bevacizumab
paclitaxel carboplatin base trial approv specif non-squam mnsclc given
view inferior os overal surviv data versu keytruda trial think tecentriq combin
take minim market share keytruda set
mnsclc think usag like split keytruda base opdivo base
tecentriq base oak see much data differenti among three agent
although keytruda approv patient express time expect number
elig patient mnsclc continu decreas patient receiv agent treatment
merck compani report factset cantor fitzgerald research
exhibit nsclc trial approv
compani report cantor fitzgerald research
trial studi detailstri approv combin pemetrex platinum chemotherapi nonsq mnsclc egfr-/alk- pembrolizumab pemetrex cisplatin/carboplatinplacebo pemetrex cisplatin/ carboplatinmedian os nr vs month hr os vs vs month hr vs vs cr pr median dor vs monthsgrad toxic vs approv combin carboplatin either paclitaxel nabpaclitaxel sq mnsclcpembrolizumab carboplatin paclitaxel/nab-paclitaxelplacebo carboplatin paclitaxel/nab-paclitaxelmedian os vs month hr os vs vs month hr vs dor vs monthsgrad toxic vs approv monotherapi mnsclc high express tp egfr-/alk- pembrolizumabinvestig choic platinum-contain chemotherapi regimensmedian os vs month hr vs month hr vs cr pr median dor nrgrade toxic vs approv monotherapi mnsclc express tp egfr /alk patient diseas progress fda-approv therapi aberr prior receiv keytruda pembrolizumabdocetaxeltp mg/kg mg/kg median os vs month hr vs month hr dor nr nrtp mg/kg mg/kg median os vs month hr vs month hr stat sig orr dor nr nrgrade toxic vs approv monotherapi squamou mnsclc egfr /alk patient diseas progress fda-approv therapi aberr prior receiv opdivo nivolumabdocetaxelmedian os vs month hr os vs vs month hr vs toxic vs approv monotherapi nonsquam mnsclc egfr /alk patient diseas progress fda-approv therapi aberr prior receiv opdivo nivolumabdocetaxelmedian os vs month hr os vs vs month hr stat sig orr vs toxic vs approv combin bevacizumab paclitaxel carboplatin first-lin treatment non-squam mnsclc egfr-/alk- arm atezolizumab paclitaxel carboplatin arm bevacizumab arm parm vs arm cmedian os vs month hr vs month hr vs dor vs monthsarm vs arm grade toxic vs approv monotherapi mnsclc diseas progress follow platinum-contain chemotherapi egfr /alk patient diseas progress fda-approv therapi aberr prior receiv tecentriq atezolizumabdocetaxelmedian os month hr month hr stat sig orr cr pr median dor monthsgrad toxic vs approv monotherapi unresect stage nsclc whose diseas progress follow concurr plat-bas chemotherapi radiat therapydurvalumabplacebomedian vs month hr vs vs dor vs toxic vs trial imfinzi durvalumab approv trial keytruda pembrolizumab approv trial opdivo nivolumab approv trial keytruda non-smal cell lung cancer nsclc current landscap
support keytruda leadership mnsclc note hand notabl failur competitor tri gain
approv set most-not base due dilig physician
gener belief fail design trial select patient whose tumor express
versu efficaci agent opdivo trial tecentriq bavencio fail meet
high bar necessari compet keytruda leadership far
compani report cantor fitzgerald research
trial studi detailstri meet primari endpoint monotherapi mnsclc whose tumor express choic chemotherapymedian os vs month hr stat sig median vs month hr stat sig consist known safeti profil previou studi grade trea vs non-squam nsclcmet co-primari endpoint stat sig os benefit observ interim analysisfin analysi expect cisplatin pemetrex carboplatin cisplatin pemetrexedinterim result median os month hr stat sig median month hr dor monthsconsist known safeti profil individu medicinesgrad trae vs squamou nsclcmet co-primari endpoint stat sig os benefit observ interim analysisstudi continu plannedarm atezolizumab paclitaxel carboplatin arm atezolizumab nab-paclitaxel carboplatin arm nab-paclitaxel carboplatin interim result arm vs arm median os vs month hr stat sig median month hr dor monthsconsist safeti profil individu medicinesseri trae arm arm arm stage iv nsclcnovemb meet os primari endpointsregulatori submiss express cancer cell median os monotherapi combo reach stat sig hr mono combo consist previou trialsjavelin lung nsclcdid meet os endpoint hazard ratio stat hazard ratio hazard ratio observ overal javelin clinic develop programfail trial trial disappoint resultsopdivo nivolumab bavencio avelumab fail trial trial disappoint resultstecentriq atezolizumab fail trial trial disappoint resultsimfinzi durvalumab fail trial trial disappoint result keytruda non-smal cell lung cancer nsclc tailwind headwind
compani report cantor fitzgerald research
trial studi detailstri submit monotherapi local advanc metastat nsclc express tp egfr-/alk- pdufa date chemotherapyinterim analysi june os vs month hr hazard ratio stat sig orr vs os vs month hr vs os vs month hr vs dor vs monthsgrad toxic vs platinum doublet chemotherapi radiotherapi unresect local advanc stage experiment cohort aexperiment cohort mnsclc part opdivo yervoy opdivo monotherapi vs chemotherapi patientspart opdivo yervoy opdivo chemotherapi vs chemotherapi patient whose tumor express opdivo chemotherapi vs chemotherapi regardless tumor mutat burden statu tmb final data part expect avail data nivolumabarm nivolumab ipilimumabarm nivolumab platinum doublet chemotherapyarm platinum doublet chemotherapi nejm public nivo ipi high tmb mut/mb regardless expressionmedian vs month chemo hr tmb hazard ratio tmb hazard ratio vs vs chemomedian dor nr vs dor vs hazard ratio earli descr data nivo ipi nivo chemo vs chemo median nr vs vs month hr nr vs vs patient high tmb median vs vs month hr nivo ipi vs chemo grade toxic vs toxic vs vs mnsclcphase data chemotherapi nsclc patient tki treatmentphas estimate primari complet date nivolumab platinum doublet stage nsclc adjuv phase data doublet chemotherapynivolumab platinum doublet chemotherapypend trial either progress process filing/approv decis opdivo nivolumab pend trial either progress process filing/approv decis keytruda pembrolizumab keytruda non-smal cell lung cancer nsclc tailwind headwind
continu uptak non squamou mnsclc eu
follow eu approv septemb
merck work reimburs
process major eu market throughout
pdufa date expect
approv would open opportun keytruda
monotherapi treatment mnsclc
less toxic patient reinforc
keytruda leadership mnsclc
keep eye phase data
expect posit data could set keytruda
potenti treatment stage nsclc set
late-stag competitor trial nsclc includ
opdivo phase data
opdivo phase data
imfinzi neptun phase data imfinzi
nsclc
sever on-going phase
bavencio javelin lung phase data
late-stag competitor trial earlier nsclc set
tecentriq adjuv
stage nsclc stage nsclc
think os data behind keytruda set substanti high bar player compet set
exampl although expect approv tecentriq data pdufa date median os data
tecentriq chemotherapi vs chemotherapi month vs month hazard ratio hr clinic
meaning view base discuss physician physician usual want see hr
similar expect imfinzi on-going trial reinforc recent failur mystic trial also
true bavencio given fail nsclc trial set javelin lung
headwind mnsclc think present biggest threat keytruda
merck compani report factset cantor fitzgerald research
keytruda non-smal cell lung cancer nsclc tailwind headwind
compani report clinicaltri gov cantor fitzgerald research
trial studi detailstri non-squam nsclcpdufa os vs month hr vs month hr vs dor vs monthsgrad toxic vs nsclc patientsrecruit complet estimate primari complet date carboplatin cisplatin pemetrex squamou carboplatin adjuv phase estimate primari complet date support neoadjuv phase estimate primari complet date chemotherapyplatinum-bas non-squam nsclccohort fulli recruit estimate primari complet date alk nsclc cohort ret nsclc cohort btmb nsclc cohort stage iv nsclc egfr/alkwt data readout stage iv nsclc egfr-/alk- data readout chemodurvalumab soc chemosoc stage iv nsclc egfr/alkwt readout chemotherapyadjuvantstag i- nsclc adjuv phase estimate primari complet date januari readout stage nsclc given concurr platinum-bas crt phase estimate primari complet date readout chemotherapi radiat placebo platinum-bas chemotherapi radiat stage nsclc consolid therapi pateint progress follow definit platinum-bas crt phase estimate primari complet date readout lung stage iv nsclc data iv everi wk plat chemotherapi regimenavelumab iv wk everi wk javelin lung phase group least one prior therapi regiment group number prior regimen estimate primari complet alk- avelumab crizotinibgroup alk avelumab parp medley phase advanc primari recurr metastat solid tumor includ nsclc tnbc hr breast cancer recurr plat-sensit ovarian cancer urotheli cancer uc crpcest primari complet nsclc phase nsclc resist ddr phase primari complet primari complet primari complet ipilimumabimfinzi durvalumab pend trial either progress process filing/approv decis libtayo cemiplimab pend trial either progress process filing/approv decis bavencio avelumab pend trial either progress process filing/approv decis tecentriq atezolizumab pend trial either progress process filing/approv decis keytruda non-smal cell lung cancer nsclc compar
exhibit comparison avail data among keynot
compani report public cantor fitzgerald research
view avail data suggest follow
data pose threat keytruda usag patient high express
like threat pose patient high tmb mut/mb express
driven view compar orr data keynot chemotherapi
import physician weve spoken view superior safeti data
trial studi detailstri armsefficaci regardless expressionefficaci nonsq mnsclc pembrolizumab pemetrex cisplatin/carboplatinplacebo pemetrex cisplatin/ carboplatinmedian os nr vs month hr os vs vs month hr vs vs cr pr median dor vs os vs hr hr vs os vs hr hr vs os vs hr hr vs toxic vs sq mnsclcpembrolizumab carboplatin paclitaxel/nab-paclitaxelplacebo carboplatin paclitaxel/nab-paclitaxelmedian os vs month hr os vs vs month hr vs dor vs os vs hr vs month hr vs os vs hr vs month hr orr vs os vs hr vs month hr vs toxic vs mnsclcarm nivolumabarm nivolumab ipilimumabarm nivolumab platinum doublet chemotherapyarm platinum doublet chemotherapi nejm public high tmb mut/mb regardless express nivo ipi vs chemo median vs month chemo hr vs vs chemomedian dor nr vs dor vs hazard ratio earli descr data nejm public nivo ipi vs chemo high tmb hazard ratio tmb hazard ratio nivo ipi nivo chemo chemo median report vs vs month hr report vs vs patient high tmb median vs vs month hr toxic vs toxic vs vs keytruda non-smal cell lung cancer nsclc compar
tmb tmb data may suggest tumor mutat burden tmb test may use new approach
identifi patient like respond therapi like opdivo yervoy opdivo chemotherapi howev
note follow barrier overcom repres more-meaning threat keytruda
part trial patient tumor sampl avail attempt assess tmb
valid data tmb-base efficaci analys due mainli limit avail tumor sampl suffici
quantiti qualiti consequ limit tissu request biomark analysi part trial nejm
public note clinic practic test mutat burden request earli decision-
make process select appropri first-lin treatment thu suffici quantiti qualiti
tumor sampl obtain submit success determin tumor mutat burden expect
patient undergo test less optimist tmb test rate real-world practic
given compar test tmb test less familiar doctor requir next-gener sequenc
panel vs immunohistochemistri use test take longer conduct coupl week vs
day test notabl period time mnsclc patient
follow discuss fda announc voluntari withdraw sbla opdivo low-
dose yervoy treatment mnsclc patient mut/mb driven belief
evid relationship tmb requir fulli evalu impact opdivo plu yervoy
os first-lin nsclc patient
conclus made concret os data recogn
progress free surviv data promis far result alway correl complet os
overal surviv result os improv remain gold standard oncologist bmi analysi relationship
tmb requir avail final data part opdivo yervoy
opdivo monotherapi versu chemotherapi patient whose tumor express anticip
avail earn made comment interim analysi lung program
compani report public cantor fitzgerald research
keytruda non-smal cell lung cancer nsclc compar
big high tmb express patient popul
estim nsclc patient express
note nejm public success determin tumor mutat burden
patient whose tmb could evalu mut/mb
expect patient undergo test
estim peak tmb test rate mnsclc patient high tmb express
patient popul address keytruda current address patient popul
therefor even account potenti impact mnsclc set
think keytruda sale mnsclc market exceed
compani report cantor fitzgerald research
aggarw et al preval express patient non-smal cell lung cancer screen enrol annal oncolog volum issu octob
local diseas evid metastas stage i-ii
accord american cancer societi new melanoma diagnos rate new
melanoma case rise averag year past year gener melanoma
categor follow
accord seer databas lung cancer diagnosi local estim patient
elig io therapi unresect metastat melanoma set
therapi unresect metastat diseas nccn guidelin current recommend checkpoint immunotherapi
braf-target therapi patient braf-mut diseas clinic trial guidelin note checkpoint
inhibitor shown effect regardless braf mutat statu option appropri
braf mutant braf wild-typ metastat diseas physician choic use monotherapi
vs combin therapi trade-off improv efficaci increas toxic
subsequ therapi set patient progress therapi achiev maximum clinic benefit
braf-target therapi braf mutat option depend ecog perform statu
ecog ps patient offer best support care
ecog ps depend braf statu treatment histori possibl therapi
immunotherapi braf-target therapi regimen includ combin braf mek inhibit nivolumab
vemurafenib dabrafenib/trametinib
vemurafenib/cobimetinib combin nccn panel recommend consid agent
class agent patient receiv previous
opdivo monotherapi also approv adjuv set melanoma patient lymph node involv
metastat diseas undergon complet resect stage iiib stage iiic iv
american cancer societi seer databas nccn guidelin access cantor fitzgerald research
base due dilig call physician view melanoma landscap follow
opdivo monotherapi soc set earn bristol note continu
see strong uptak new launch adjuv melanoma hold share marketplac
accord doctor spoken receiv adjuv set exclud patient
receiv one later line therapi gener rule thumb patient progress month
receiv like opdivo monotherapi doctor feel comfort re-challeng pd-
monotherapi combin
braf mutant brafm one physician spoke note brafm patient receiv
immunotherapi receiv braf inhibitor
patient receiv immunotherapi receiv opdivo yervoy receiv either
opdivo keytruda monotherapi
notabl physician spoken say driver behind use opdivo monotherapi
keytruda monotherapi better dose schedul everi four week
infus opdivo vs everi three week infus keytruda merck work
braf wildtyp brafwt one physician spoke note brafwt melanoma patient
receiv treatment either singl agent keytruda opdivo combin opdivo
second-lin subsequ line melanoma
assum treatabl melanoma patient set could decreas modestli time
patient treat io set
merck share detail regulatori strategi dose yet data support dose
regimen physician spoke awar data think conveni dose keytruda vs
opdivo could shift usag keytruda favor especi vs opdivo monotherapi efficaci safeti data
compar view
merck compani report factset cantor fitzgerald research
exhibit melanoma trial approv
compani report cantor fitzgerald research
detailstri approv monotherapi treatment patient unresect metastat melanoma ipilimumab-nav pembrolizumab pembrolizumab hazard ratio os vs vs month hr vs posit os hr neg os hr hazard ratio os vs vs month hr vs posit os hr neg os hr toxic vs approv monotherapi treatment patient unresect metastat melanoma ipilimumab-refractori pembrolizumab mg/kg pembrolizumab mg/kg inv-choic chemo icc iccpembro mg/kg iccpembro mg/kgall pembro dose amend mg mg/kg os vs month hr stat sig median vs month hr vs vs mg/kg os vs month hr stat sig median vs month hr vs vs toxic vs high-risk stage melanoma adjuv pembrolizumabplacebograd toxic vs approv monotherapi previous untreat metastat melanoma braf wild-typ unresect metastat melanoma nivolumabdacarbazinegrad toxic vs approv monotherapi previous treat metastat melanoma without braf mutation-posit melanoma nivolumabinvestig choic chemotherapygrad toxic vs approv combin ipilimumab previous untreat unresect metastat melanomanivolumab ipilimumab placebo nivolumab placebonivolumab ipilimumab nivolumab placeboipilimumab nivolumab placeboesmo lancet public dataipi nivo median os reach vs month hr os rate vs vs month hr rate cr vs cr esmo lancet public datanivolumab median os vs month hr os rate vs vs month hr rate cr vs cr grade toxic vs approv monotherapi adjuv set melanoma patient lymph node involv metastat diseas undergon complet resectionipilimumab nivolumab placebonivolumab ipilimumab placeboasco datarf vs hr stage vs stage vs stage iv vs vs vs brafm vs brafwt vs publicationcomplet treatment vs rf nr either rf vs rf vs toxic vs nejm recurrence-fre surviv rf vs recurr death rf vs rf vs recurr death recurr death analysi median os reach vs month hr os vs vs month hr vs os vs month hr os vs os vs vs month hr vs dor vs monthskeytruda pembrolizumab approv trial opdivo nivolumab approv trial februari
keytruda melanoma tailwind headwind
approv announc
open opportun keytruda treatment
potenti approv more-conveni dose regimen
keytruda merck present poster
potenti dose keytruda also note
on-going phase trial studi subcutan
also explor
keytruda opdivo
data estimate primari complet date
octob posit data could open
opportun stage ii melanoma adjuv see
opportun upsid current estim
late-stag competitor trial adjuv melanoma
tecentriq phase data file
tecentriq phase data file
complet date august
opdivo phase data
novartiss checkpoint inhibitor develop
spartalizumab phase data
potenti launch
phase platform trial expect
complet plan file
upcom expect approv adjuv melanoma think keytruda take meaning share away
opdivo said assum opdivo retain major share adjuv set due first-to-
merck share detail regulatori strategi dose yet physician spoke awar
data think more-conveni dose keytruda vs opdivo could shift usag keytruda favor
especi vs opdivo monotherapi efficaci safeti data compar view
tecentriq phase trial studi tripl combin therapi brafm melanoma atezolizumab mek
inhibitor cobimetinib braf kinas inhibitor vemurafenib dual combin therapi
melanoma atezolizumab cobimetinib reserv use tripl combin therapi given
expect increas toxic especi given impress four-year os data opdivo yervoy
also assum minim market share taken dual therapi given bolu data would
compet
compani report factset cantor fitzgerald research
keytruda melanoma tailwind headwind
exhibit melanoma pend fail late-stag trial
compani report cantor fitzgerald research
detailstri high-risk stage ii melanoma adjuv estim primari complet date termin april incyte/merck pembrolizumab epacadostat pembrolizumab placebo stage iiib/c/d iv melanoma adjuv phase data w/ metastat melanomaphas estimate primari complet date braf mutant brafm melanomafil submiss vemurafenib vemurafenib placeboatezolizumab placebo cobimetinib vemurafenib wild-typ brafwt melanomafil submiss trial trial disappoint resultstecentriq atezolizumab pend trial either progress process filing/approv decis pend trial either progress process filing/approv decis opdivo nivolumab pend trial either progress process filing/approv decis keytruda pembrolizumab februari
keytruda melanoma thought adjuv opportun
one differ keytruda trial opdivo trial focus patient
complet resect high-risk stage melanoma stage melanoma patient stage melanoma
least one micrometastasi measur mm greatest diamet stage iiib iiic diseas in-transit
metastas includ stage iiib stage iic iv melanoma clinic practic howev imagin physician
administ treatment option similar patient popul doctor spoken said data
adjuv trial compar
keytruda adjuv treatment stage ii melanoma estimate primari complet date roughli
octob see upsid current estim early-stag melanoma surgic resect
standard treatment typic associ posit long-term prognosi five-year melanoma-specif
surviv rate stage melanoma believ larger opportun stage diseas
patient region involv diagnosi higher risk recurr loco-region resect
like die metastat diseas nccn guidelin current state patient very-low-risk stage iiia
diseas non-ulcer primari sln metastasi toxic adjuv therapi may outweigh benefit
think opdivo opdivo yervoy adjuv therapi resect stage iiib/c/d iv melanoma
good chanc show posit efficaci given success/dur efficaci combin treatment
impress four-year os rate although toxic concern lead us believ good subset patient stay
monotherapi adjuv treatment option phase data expect
success opdivo monotherapi adjuv treatment melanoma given us reason remain optimist
adjuvant/neoadjuv opportun tumor type recent fda-approv adjuv treatment option
melanoma interferon ifn success late-stag trial checkpoint inhibitor target agent
combi-ad dabrafenib/tafinlar nv cover trametinib/mekinist nv cover resect stage braf-
mutat melanoma increas treatment option physician could expect
similar opportun open tumor type like rcc tnbc gastric cancer opportun
note merck
nccn guidelin cantor fitzgerald research
long georgina et al adjuv dabrafenib plu trametinib stage braf-mut melanoma novemb engl
metastat rcc prognost score system develop stratifi risk group patient favor
intermedi poor risk stand opdivo yervoy becom soc standard treatment patient
intermedi poor risk advanc clear cell rcc driven data show superior
efficaci safeti data vs previou soc sunitinib sutent sutent pazopanib votrient remain soc patient
favor risk advanc rcc bristol note opdivo yervoy becom standard-of-car mani
 set rcc recent quarter said opdivo sale come renal indic
estim patient rcc
exhibit nccn guidelin renal cell carcinoma
access cantor fitzgerald research
keytruda renal cell carcinoma rcc tailwind headwind
given impress data recent present gu think probabl
outcom keytruda axitinib inlyta combin becom new soc treatment favor risk
patient usurp sunitinib sutent believ base earli promis data
intermediate/poor risk patient popul equal split opdivo keytruda pend posit
longer efficaci data exclud assumpt around success opdivo
compani report nccn guidelin cantor fitzgerald research
detailstri renal cell carcinomapdufa date gu first interim os vs hazard ratio vs month hr vs nr vs monthsconsist across imdc risk group expressiongrad toxic vs lead discontinu vs approv monotherapi patient advanc renal cell carcinoma receiv prior antiangiogen therapynivolumabeverolimusnovemb nejm public median os vs month hr hazard ratio favor risk hazard ratio intermedi risk hazard ratio poor risk vs month hr stat sig orr vs dor vs monthsgrad toxic vs approv combin ipilimumab patient intermedi poor risk advanc renal cell carcinomanivolumab ipilimumabsunitinibesmo april nejm asco gu os nr vs month hr os vs hr os vs os vs vs month hr stat orr vs cr vs vs respons orr vs dor nr vs monthsgrad toxic vs lead discontinu vs pembrolizumab pend trial either progress process filing/approv decis opdivo nivolumab approv trial februari
keytruda renal cell carcinoma rcc tailwind headwind
pdufa date lowest
hang fruit keytruda axitinib like
new soc favor risk advanc rcc patient
advanc rcc patient
lenvima well lenvatinib everolimu phase
estimate primari complet date april
adjuv rcc phase estimate primari
complet date novemb follow
rcc shakeout expect adjuv rcc core
focu class least three player
late-stag competitor trial rcc includ
fda ema
complet summer
bavencio javelin renal fda file
opdivo phase data
estimate primari complet date decemb
late-stag competitor trial adjuv rcc includ
opdivo phase data
complet date may
addit becom new soc favor risk advanc rcc patient think keytruda axitinib
inlyta combin take share away opdivo yervoy intermediate/poor risk patient although
think opdivo yervoy shown great durabl efficaci os data doctor spoken
note commun doctor still compar less comfort deal greater incid
immune-rel advers event brought io/io combin compar grade
higher vs vs tr lead discontinu lower vs
moreov apples-to-appl basi think interim data clearli look better
data term os orr
next big potenti near-term headwind look opdivo cabozantinib
cabometyx combin intermediate/poor risk rcc patient compet directli
merck compani report factset cantor fitzgerald research
keytruda renal cell carcinoma rcc tailwind headwind
immunotherapi anti-vegf tki combin approach repres futur treatment approach
rcc view reflect on-going combin trial
pankit vachhani md sabi georg md vegf inhibitor renal cell carcinoma clinic advanc hematolog oncolog decemb volum issu
keytruda renal cell carcinoma rcc tailwind headwind
list rcc data vegf inhibitor studi combin
cabozantinib cabometyx manufactur exelixis/not cover open-label phase trial cabosun
random patient intermedi poor risk advanc rcc therapi either cabozantinib mg
daili sunitinib mg daili wk wk patient treat cabozantinib show significantli
increas median compar treat sunitinib vs month cabozantinib also show
significantli higher orr object respons rate compar sunitinib vs all-caus grade
cabozantinib sunitinib
axitinib inlyta manufactur pfizer/overweight random open-label phase trial newli diagnos
patient receiv axitinib mg twice daili sorafenib mg twice daili axitinib versu sorafenib yield
numer longer median vs month hr significantli higher orr vs median os
vs month hr sae report axitinib-tr patient vs sorafenib-
bevacizumab avastin manufactur genentech/not cover studi along interferon therapi clear
bevacizumab ifn- significantli increas vs month orr vs signific increas
novel observ combin ifn- alon numer trend toward improv os
observ vs month most-commonli report grade fatigu vs asthenia
lenvatinib lenvima co-develop co-commerci eisai/not cover merck lenvatinib everolimu
list categori recommend subsequ therapi nccn kidney cancer panel phase trial
patient metastat unresect local advanc clear cell rcc receiv prior antiangiogen therapi
randomli assign lenvatinib everolimu lenvatinib single-ag everolimu significantli
prolong lenvatinib everolimu vs everolimu vs month hr median os also increas
vs month hr median os lenvatinib alon month
compani report nccn guidelin cantor fitzgerald research
keytruda renal cell carcinoma rcc tailwind headwind
compani report cantor fitzgerald research
detailstri renal cell carcinomapdufa date gu first interim os vs hazard ratio vs month hr vs nr vs monthsconsist across imdc risk group expressiongrad toxic vs lead discontinu vs cell carcinoma adjuv phase estimate primari complet date renal cell carcinomaphas estimate primari complet date renal cell carcinomaphas estimate primari complet date pazopanibincyt sever combin trial on-going epacadostat given disappoint result see neg readthrough remain late-stag cell carcinoma adjuv phase data renal cell carcinoma intermediate/poor risk phase data cabozantinib w/ renal cell carcinomaphas estimate primari complet date decemb rccfda ema file complet summer gu co-primari endpoint median vs month hr vs dor nr vs monthsitt populationmedian vs month hr descr orr vs dor vs monthsgrad toxic vs cell carcinoma adjuv phase estimate primari complet date renal rccpdufa date june co-primari endpoint median vs month hr vs populationmedian vs month hr vs toxic vs trial either progress process filing/approv decis tecentriq atezolizumab pend trial either progress process filing/approv decis keytruda pembrolizumab pend trial either progress process filing/approv decis opdivo nivolumab pend trial either progress process filing/approv decis keytruda renal cell carcinoma rcc compar io vegf trial
note base data present gu think posit keytruda inlyta soc
treatment advanc rcc favor risk patient
trial studi keytruda lenvatinib lenvima well lenvatinib everolimu novartiss afinitor
success either combin would good merck given eisai merck co-develop co-
commerci lenvima probabl posit outcom support earlier clinic data
esmo pool result phase clinic trial patient treat keytruda lenvima
orr respons seen treatment-nav patient previous treat patient
patient also seen patient patient patient
asco longer follow-up data combin demonstr orr median month
median dor month grade occur patient discontinu treatment due ae
phase estimate primari complet date april lenvima keytruda grant fda breakthrough therapi
design treat patient advanc rcc could help acceler approv
earli data keytruda lenvatinib combin encourag trial demonstr similar orr
phase trial would put ahead trial like immot javelin renal
shown orr rang potenti upsid get posit data could posit
keytruda lenvima combin keytruda inlyta inlyta manufactur
opdivo cabozantinib combin limit rcc avail data
phase trial patient previous treat genitourinari tumor cabozantinib monotherapi shown
significantli higher orr sunitinib vs without significantli increas toxic grade vs
doctor spoken said gener comfortable/us use cabozantinib axitinib
rcc vs lenvatinib newer less-familiar drug
compani report cantor fitzgerald research
conduct clinic develop collabor bristol evalu cabometyx
cabozantinib opdivo primari efficaci analysi compar doublet combin vs sunitinib
esmo phase data patient previous treat genitourinari tumor twenty-four patient accru
metastat urotheli carcinoma urach adenocarcinoma squamou cell carcinoma bladder urethra
germ cell tumor castration-resist prostat cancer renal cell carcinoma trophoblast tumor
treat part studi evalu combin cabozantinib nivolumab four dose level median
number prior system therapi three patient receiv four prior therapi orr
patient evalu respons
gu forty-eight patient accru previous treat metastat urotheli carcinoma urach
adenocarcinoma squamou cell carcinoma bladder urethra germ cell tumor castration-resist
prostat cancer renal cell carcinoma trophoblast tumor sertoli cell tumor penil squamou cell
carcinoma part patient treat doublet combin cabozantinib nivolumab four dose level
part ii patient treat triplet combin cabozantinib nivolumab ipilimumab three dose level
among patient evalu respons orr tumor type doublet dose schedul
triplet dose schedul grade observ doublet combin includ neutropenia hypophosphatemia
hypertens lipas increas fatigu diarrhea dehydr limit number
grade doublet combin grade observ either part trial
note third arm look tripl combin opdivo yervoy cabozantinib
discontinu think decis could possibl driven toxic
read less posit data believ intermediate/poor risk patient
popul equal split opdivo keytruda pend posit longer efficaci data
read data compar think opdivo retain major share
rcc market opdivo share keytruda share remain share go tecentriq
bavencio like scenario view assum model
read data view favor compar think opdivo could retain larger
major market keytruda second-highest share follow bavencio tecentriq
compani report cantor fitzgerald research
javelin renal alreadi present data either file process file
studi combin tecentriq bevacizumab avastin javelin renal studi
combin bavencio axitinib inlyta
exhibit javelin renal phase data
compani report cantor fitzgerald research
although javelin renal demonstr posit efficaci safeti profil
think met necessari bar outweigh data
receiv approv treatment intermedi poor risk patient regardless statu also
demonstr efficaci across risk group regardless statu unclear us tecentriq
avastin bavencio inlyta would fit treatment landscap said think expect pfizer bavencio
inlyta modest none meaning sale would repres upsid expect
detailstri rccfda ema file complet summer gu co-primari endpoint median vs month hr vs dor nr vs monthsitt populationmedian vs month hr descr orr vs dor vs monthsgrad toxic vs renal rccfda file co-primari endpoint median vs month hr vs populationmedian vs month hr vs toxic vs trial either progress process filing/approv decis tecentriq atezolizumab pend trial either progress process filing/approv decis februari
bristol on-going phase combin trial opdivo rcc
decis move phase rcc base phase pivot studi evalu opdivo
patient melanoma rcc urotheli nsclc tnbc pre-specifi efficaci criteria achiev melanoma
rcc urotheli cancer present
pre-specifi efficaci criteria met object respons rate orr stage patient
achiev either partial respons pr complet respons cr median time studi patient stage
month respons observ patient cr pr upr among patient known
statu orr neg patient posit patient one patient
unknown baselin statu experienc cr
pre-specifi efficaci criteria met orr stage patient achiev partial respons
pr median time studi patient stage month respons observ
patient pr upr among patient known statu orr neg patient
posit patient one two patient unknown baselin statu
pre-specifi efficaci criteria met orr stage patient achiev either partial
complet respons ucr pr upr median time studi patient stage month orr
neg patient posit patient
doctor spoken gener neg expect combin trial cite opac
avail data specif lack inform durat respons earlier clinic trial result
current ascrib valu combin
compani report cantor fitzgerald research
current approv inhibitor tripl neg breast cancer tnbc also known hormone-
compar diseas present metastat breast cancer keytruda competitor on-going trial
neoadjuv adjuv set
exhibit treatment option tripl neg breast cancer
compani report nccn guidelin access cantor fitzgerald research
accord american cancer societi estim case invas breast cancer
women tnbc repres breast cancer accord seer patient metastat breast
cancer mbc present de novo metastat diseas merck keytruda chemotherapi assess
patient local recurr inoper metastat tnbc previous treat chemotherapi
estim drug-treat patient base criteria
chemotherapi current soc treatment tnbc adjuv neoadjuv metastat set tnbc
highli sensit chemotherapi evidenc patholog complet respons pcr rate rang
neoadjuv chemotherapi compar complet respons cr rate er-posit breast cancer rang
howev tnbc higher rate relaps
parp inhibitor like lynparza olaparib talzenna talazoparib newer treatment approv treat mtnbc although
treatment limit patient germlin brca-mut gbrcam present among newli diagnos breast
cancer patient mutat gene present tnbc
phase data studi tecentriq nab-paclitaxel first pivot data demonstr
potenti treatment tnbc accord doctor spoken surviv benefit seen
express popul clinic meaning hard-to-treat patient popul
compar grade toxic rate control arm placebo nab-paclitaxel combin expect becom
soc tnbc
given posit data tecentriq nab-paclitaxel see posit read-through
couch fergu et al inherit mutat breast cancer suscept gene among larg triple-neg breast cancer cohort unselect famili histori breast cancer journal
clinic oncolog offici journal american societi clinic oncolog volume
peshkin beth et al mutat tripl neg breast cancer breast diseas volume
dua isha et al immunotherapi triple-neg breast cancer focu immun checkpoint inhibitor american journal hematology/oncolog volume
keytruda tripl neg breast cancer tnbc tailwind headwind
compani report clinicaltri gov cantor fitzgerald research
detailstri neg breast cancer tnbc neoadjuv adjuv phase data surgeri pembrolizumab afterplacebo chemo surgeri placebo tnbcphase data tnbc local recurr inoper mtnbc previous treat chemotherapi phase data stage breast cancer combin w/ neoadjuv chemo adjuv endocrin therapi phase estimate primari complet date tnbc nejm public populationmedian vs month hr vs stat sig median os vs month hr stat populationmedian vs month hr vs stat sig median os vs month hr formal test stat sig due hierarch test grade toxic vs neoadjuv phase estimate primari complet date tnbcphase estimate primari complet date tnbcphase estimate primari complet date carboplatin/gemcitabineplacebo capecitabin adjuv phase estimate primari complet date high-risk local advanc tnbc neoadjuv phase estimate primari complet date may neoadjuv adjuv phase estimate primari complet date breast cancer neoadjuv phase estimate primari complet date ddac-pachp placebo ddac-pachp javelin parp medley phase advanc metastat solid tumorsest primari complet tnbc phase trial either progress process filing/approv decis tecentriq atezolizumab pend trial either progress process filing/approv decis keytruda pembrolizumab pend trial either progress process filing/approv decis februari
keytruda tripl neg breast cancer tnbc tailwind headwind
posit keytruda chemotherapi new soc
treatment tbnc
posit keytruda monotherapi new soc treatment
tbnc
posit keytruda usag neoadjuv
adjuv set tnbc
late-stag competitor trial tnbc
tecentriq pdufa date
expect approv tecentriq nab-paclitaxel
like first-to-market tnbc assum tecentriq nab-paclitaxel retain
lead market share patient popul pend data doctor spoken appreci
data popul say would put patient good perform score
tecentriq nab-paclitaxel therefor even tecentriq approv patient anticip decent
amount off-label use
posit data could also produc meaning sale keytruda monotherapi tnbc set
knowledg checkpoint inhibitor on-going late-stag studi patient said
expect success outcom low base earlier clinic data phase trial cohort
trial look neoadjuv and/or adjuv set view
potenti posit data upsid estim earn merck note chanc share earli data
agenc agre import get addit data longer term follow-up
wait studi data avail chanc look care
cours share
compani report public cantor fitzgerald research
note parp inhibitor like lynparza olaparib talzenna talazoparib newer treatment approv treat
mtnbc treatment limit patient germlin brca-mut gbrcam present among newli diagnos
breast cancer patient mutat gene present tnbc
lynparza approv patient deleteri suspect deleteri gbrcam metastat breast cancer
treat chemotherapi neoadjuv adjuv metastat set patient hr breast cancer
treat prior endocrin therapi consid inappropri endocrin therapi
talzenna approv treatment adult patient deleteri suspect deleteri germlin brca-mut
gbrcam local advanc metastat breast cancer
result talzenna phase embraca trial compar talazoparib vs standard therapi follow
median month vs month hr ci hazard ratio tnbc subgroup
median os interim analysi month vs month hr ci
grade seriou advers event occur talazoparib group vs standard-therapi group
compar embraca anticip signific impact parpi tnbc
compani report cantor fitzgerald research
keytruda head neck cancer current landscap
accord nccn guidelin estim new case oral caviti pharyng laryng cancer
occur squamou cell carcinoma variant histolog type tumor
patient present early-stag diseas stage ii leav major patient present local
region advanc diseas diagnosi hnscc tumor cell known exhibit high level express
exhibit nccn guidelin head neck cancer
note unless otherwis specifi regimen list use either nasopharyng non-nasopharyng cancer
compani report nccn guidelin access cantor fitzgerald research
keytruda head neck cancer current landscap
soc treatment regimen recurr and/or metastat r/m hnscc cetuximab
fu extrem regimen demonstr median os month respons rate median
month howev patient experi diseas progress therapi platinum refractori
seldom respons treatment respons rate second-lin therapiestyp methotrex cetuximab
taxanesthat rang
current keytruda opdivo monotherapi approv treatment diseas progress
platinum-contain chemotherapi
phase trial form basi approv keytruda monotherapi treatment patient
recurr metastat hnscc diseas progress platinum-contain chemotherapi respons
heavili pretreat popul compar favor observ single-ag cetuximab orr dor four
month also median os par longest median surviv report patient treatment-na r/m
hnscc month achiev extrem regimen similar observ afatinib patient
previous treat r/m diseas month contrast signific toxic observ extrem regimen
pembrolizumab well-toler
keynot trial cite nccn guidelin
nonrandom phase studi patient recurr metastat nasopharyng
carcinoma npc patient two previous receiv system therapi recurr metastat
diseas orr median dor month month os month os rate
respect rate grade toxic updat nccn guidelin vote
includ pembrolizumab patient previous treat recurr metastat npc categori
nonrandom phase studi patient hnscc progress follow treatment
platinum cetuximab orr mean dor eight month grade toxic
compani report cantor fitzgerald research
chow haddad gupta mahip mehra tahara seiwert antitumor activ pembrolizumab biomarker-unselect patient recurr
and/or metastat head neck squamou cell carcinoma result phase ib expans cohort journal clinic oncolog
keytruda head neck cancer current landscap
form basi approv opdivo hsncc studi includ patient recurr hnscc
whose diseas progress within six month follow platinum-bas chemotherapi per nccn guidelin
data indic nivolumab prolong surviv patient recurr metastat hnscc
progress platinum-bas chemotherapi rel patient receiv standard single-ag system therapi
base data far nccn guidelin recommend opdivo categori recommend keytruda categori
recommend note express may associ better outcom treatment
immunotherapi recurr metastat hnscc greater likelihood respons keytruda greater surviv
benefit respons opdivo
optimist remain opportun hnscc keytruda although keytruda current approv
later line therapi merck note keytruda sale came hnscc
think movement set provid meaning upsid sale next month merck
submit sbla keytruda monotherapi combin platinum
chemotherapi recurr metastat hnscc sbla base part data pivot phase
trial keytruda demonstr signific improv overal surviv compar
standard care monotherapi patient whose tumor express
combin chemotherapi total patient popul fda grant prioriti review pdufa
date
compani report cantor fitzgerald research
chow haddad gupta mahip mehra tahara seiwert antitumor activ pembrolizumab biomarker-unselect patient recurr
and/or metastat head neck squamou cell carcinoma result phase ib expans cohort journal clinic oncolog
keytruda head neck cancer tailwind headwind
exhibit head neck cancer trial approv
compani report clinicaltri gov cantor fitzgerald research
detailstri phase approv monotherapi treatment patient recurr metastat hnscc diseas progress platinum-contain chemotherapypool analysi long term follow-up hnscc initi cohort mg/kg expand cohort mg dor nr respons on-going pt median follow-up month median os os durat date year grade toxic approv monotherapi patient r/m hnscc diseas progress platinum-bas therapynivolumab cetuximab/methotrexate/docetaxel median os vs month hr os rate vs vs month hr stat sig orr vs stat os vs month hr os vs month hr toxic vs trial opdivo nivolumab approv trial keytruda pembrolizumab februari
keytruda head neck cancer tailwind headwind
next area growth keytruda hnscc set driven posit data interim
analysi releas esmo view posit data
although meet primari endpoint consid result posit given poor
prognosi r/m hnscc improv toxic demonstr keytruda arm patient soc arm
receiv subsequ immunotherapi potenti affect os includ support data
sbla indic base
think data suggest keytruda monotherapi becom soc treatment pd-
patient driven especi improv toxic profil vs current soc extrem regimen also think
data support keytruda chemotherapi soc treatment approach hsncc regardless express
exhibit clinic data
compani report public clinicaltri gov cantor fitzgerald research
detailstri r/m hnsccpdufa date confirmatori trial extrem esmo interim analysi os vs month hr vs dor vs monthsdid prolong os vs month hr vs dor vs monthstot populationmedian os non-inferior vs chemoorr vs dor vs monthsesmo interim analysi combin regardless expressionmedian os vs month hr vs dor vs monthso significantli superior interim analysisgrad toxic hnscc platinum-bas chemotherapi includ support data sbla indic base standard treatment methotrex docetaxel cetuximab esmo popul os assess stat sig median os vs month hr stat os rate vs vs month hr vs esmo os vs month hr os rate vs vs month hr vs tp os vs month hr os rate vs vs month hr vs toxic vs pembrolizumab pend trial either progress process filing/approv decis keytruda head neck cancer tailwind headwind
expect approv posit keytruda monotherapi
combin chemotherapi new soc
nasopharyng cancer npc view upsid
late-stag competitor trial hnscc
opdivo phase data
opdivo phase data
bavencio javelin head neck phase data
local advanc hnscc
support keytruda potenti treatment
approv space libtayo
late-stag competitor trial adjuv hnscc
complet octob
august
expect posit outcom imfinzi kestrel trial given failur eagl trial stage iv hnscc
use trial arm decemb astrazeneca announc eagl meet primari endpoint os
improv vs soc chemotherapi either imfinzi monotherapi imfinzi tremelimumab compani anti
neg eagl data also provid neg read-through view
given studi look anoth io-io combin case yervoy ipilimumab
said data provid import look efficacy/safeti profil opdivo yervoy
given think keytruda monotherapi keytruda chemotherapi abl lead r/m hnscc
compani report cantor fitzgerald research
keytruda head neck cancer tailwind headwind
exhibit head neck pend fail late-stag trial
compani report public clinicaltri gov cantor fitzgerald research
detailstri advanc hnscc concomitantli chemoradi mainten therapi phase estimate primari complet date hnscc given prior surgeri combin radiotherapi given post-surgeri phase estimate primari complet date neoadj pembrolizumab soc adj neoadj soc nasopharyng cancer npc phase data phase r/m la unresect cutan squamou cell carcinoma cscc phase data cscc cohortla cscc r/m hnscc phase data phase r/m hnsccphase data elig local advanc hnscc adjuv phase estimate primari complet date placebo radiotherapycetuximab nivolumab placebo radiotherapycohort placebo local advanc hnscc adjuv phase estimate primari complet date stage iv hnsccdata readout regulatori submiss stage iv hnsccdurvalumabdurvalumab tremelimumab chemotherapydecemb combo meet primari endpoint os improv vs soc chemotherapyconsist previou experiencejavelin head neck local advanc hnsccphase data crtplacebo soc crtpend trial either progress process filing/approv decis opdivo nivolumab pend trial either progress process filing/approv decis keytruda pembrolizumab bavencio avelumab pend trial either progress process filing/approv decis tecentriq atezolizumab pend trial either progress process filing/approv decis imfinzi durvalumab pend trial either progress process filing/approv decis fail trial trial disappoint result keytruda gastric cancer
keytruda current approv treatment gastric cancer approv monotherapi
recurr local advanc metastat gastric gastroesophag junction adenocarcinoma patient whose tumor
express diseas progress two prior line therapi includ fluoropyrimidine-
platinum-contain chemotherapi appropri therapi
exhibit nccn guidelin gastric cancer
compani report nccn guidelin access cantor fitzgerald research
keytruda gastric cancer tailwind headwind
given prior fail trial treatment gastric cancer variou line therapi
javelin gastric cautiou keytruda opportun tumor type
public clinicaltri gov cantor fitzgerald research
detailstri phase approv monotherapi recurr local advanc metastat gastric gastroesophag junction adenocarcinoma whose tumor express determin fda-approv test diseas progress two prior line therapi includ fluoropyrimidine- platinum-contain chemotherapi appropri therapyprevi treat line pembrolizumab nave pembrolizumab cisplatin japan capecitabin nave pembrolizumab median os os dor monthsesmo dor monthsmedian os os dor monthsmedian os os toxic advanc gastric cancer data cancer neoadjuv adjuv phase estimate primari complet date placebo chemotherapypembrolizumab flot safeti cohort placebo flot safeti cohort advanc gastric cancer grade toxic vs asia basi approv japan monotherapi treatment unresect advanc recurr gastric cancer progress chemotherapynivolumabplacebograd toxic vs gastric gastroesophag junction cancer data oxaliplatin capecitabin folfox oxaliplatin leucovorin fluorouracil nivolumab xelox nivolumab folfox javelin gastric mainten gastric cancerphas data oxaliplatin-fluoropyrimidin doublet javelin gastric gastric cancerphysician choic chemotherapi best support bsc avelumab bscgrade toxic vs annal oncolog publicationmedian os vs month hr stat sig median vs month hr stat sig orr vs stat sig bavencio avelumab pend trial either progress process filing/approv decis fail trial trial disappoint resultsfail trial trial disappoint resultspend trial either progress process filing/approv decis keytruda pembrolizumab approv trial pend trial either progress process filing/approv decis opdivo nivolumab approv os vs month hr stat sig median vs month hr stat sig median os vs month hr os rate vs os rate vs vs month hr vs keytruda combin therapi competit
keytruda assess combin therapi nektar
keep eye variou combin explor nektar therapeuticss
agonist design stimul patient immun system fight cancer
design grow specif cancer-kil cell natur killer nk cell popul bodi fight cancer
known endogen tumor-infiltr lymphocyt til stimul cancer-kil immun cell
bodi target specif receptor found surfac immun cell known effector cell
natur killer nk cell also known receptor beta subunit key signal
receptor known increas prolifer effector cell clinic preclin studi treatment
result expans cell mobil tumor micro-environ
antibody-lik dose regimen similar exist checkpoint inhibitor class approv medicin
preclin studi demonstr mean ratio within tumor micro-environ
effector cell promot tumor destruct compar regulatori cell type cell
suppress tumor-kil cell furthermor singl dose result auc exposur within
tumor compar equival dose exist therapi enabl first time antibody-lik dose
regimen cytokin dose studi non-human primat evid sever side effect low
blood pressur vascular leak syndrom predict clinic therapeut dose rang
potenti use multipl tumor type includ melanoma seriou type skin cancer kidney cancer
non-smal cell lung cancer common form lung cancer
phase studi evalu singl agent patient local recurr metastat solid tumor includ
melanoma renal cell carcinoma rcc bladder colorect solid tumor complet result phase trial
present asco annual meet show encourag evid anti-tumor activ favor
safeti toler profil
merck compani report factset cantor fitzgerald research
keytruda assess combin therapi
februari exelixi bristol-my announc enter clinic develop collabor
evalu cabometyx cabozantinib small molecul inhibitor receptor tyrosin kinas opdivo
nivolumab bristol-my squibb immun checkpoint inhibitor either alon combin yervoy
ipilimumab clinic develop program co-fund compani expect includ phase
pivot trial first-lin renal cell carcinoma addit trial plan bladder cancer hepatocellular carcinoma
potenti tumor type
bristol-my split cost develop combin put phase test
roch partnership big pharma provid tecentriq pay clinic expens enrol
trial slate begin
merck compani report factset cantor fitzgerald research
keytruda potenti competit player
compani report cantor fitzgerald research compani exhibit cover except neutral alethia young
productcompanymarket cap moaindicationdevelop phase nct nsclcpivot phase hccpivot phase esophag squamou cell carcinomapivot phase hccpivot phase confirmatori clinic trial post-approv requir acceler approv r/r nk/t-cell lymphomasphas dose expans solid tumorsphas tumor /- tislelizumab phase monotherapi combin yervoy ipilimumab zelboraf vemurafenib certain cancersphas proclaim program initi clinic data present esmo bioscienc inc metastat gastroesophag cancer gec colorect cancer phase stage ovarian cancer combo zejula niraparib phase first tumour includ metastat endometri cancer phase garnet variou tumor typesphas metastat cancer /- bevacizumab niraparib carboplatin-paclitaxel phase endometri cancerclin proof conceptmerkel cell carcinomaphas primari complet date septemb cancerphas primari complet date decemb solid tumor nsclc uc melanoma rcc phase primari complet date septemb tumorsfirst-in-human studi tumorsproof tumors/hemephas tumorsphas mutant metastat melanoma combo tafinlar dabrafenib mekinist trametinib phase present submiss treat unresect metastat melanoma platform complet file cancerphas zejula niraparib combophas quest primari complet tumorsphas ltd inc formerli plc gsk tesaro acquir corpor johnson johnson spartalizumab novarti ag lynparza lenvima
think lynparza olaparib lenvima lenvatinib two addit oncolog asset could meaning
contributor compani revenu growth target merck strateg busi develop
accord compani help posit merck expand leadership oncolog
juli merck astrazeneca cover enter global strateg oncolog collabor co-develop
co-commerci astrazeneca lynparza multipl cancer type monotherapi combin trial
compani also jointli develop commerci astrazeneca selumetinib oral potent select mek
inhibitor current develop multipl cancer indic
lynparza
astrazeneca merck share
selumetinib monotherapi combin therapi opportun independ merck
astrazeneca develop commerci lynparza selumetinib combin respect pd-
develop commerci cost
gross profit lynparza selumetinib product sale gener monotherapi combin therapi
share equal
merck record share lynparza product sale net cost sale commerci cost allianc revenu
within segment share develop cost associ collabor part
 expens
part agreement merck made up-front payment astrazeneca make payment
total multi-year period certain licens option agreement also provid addit
conting payment merck astrazeneca relat success achiev regulatori sales-bas
mileston
merck compani report transcript cantor fitzgerald research
lynparza olaparib inhibitor poli adp-ribos polymeras parp enzym includ parp
enzym involv normal cellular function dna transcript dna repair olaparib-induc cytotox cell
death thought caus
inhibit enzymat activ inhibitor pi inhibit ylation abil produc chain
compet bind nad interfer abil recruit appropri dna
repair factor site dna damag result accumul singl strand break ssb ultim format
doubl strand break dsb
increas format parp-dna complex olaparib thought trap dna format parp-dna
complex shown result signific cytotox beyond caus unrepair ssb caus parp
parpi work induc dsb tumor appar defect homolog dna repair seem
suscept parpi therapi includ tumor associ germlin somat mutat
gene help repair dna damag cell mutat gene prevent make need
repair mean cancer cell brca gene mutat need reli parp repair dna parpi inhibit action parp
make difficult cancer cell repair dna damag
lynparza lead parp inhibitor parpi class new total prescript sale grow significantli
driven growth ovarian cancer well uptak breast cancer
accord merck numer futur studi lynparza address expand opportun breast prostat pancreat
cancer also data combin studi lynparza keytruda may emerg near futur
compani report fda label cantor fitzgerald research
bixel hay jl olaparib manag ovarian cancer pharmgenom per publish aug
olaparib merck/astrazenecadecemb capsul august tablet azn azn niraparib glaxosmithklin cover march rucaparib clovi cover decemb talazoparib overweight octob origin approvalsal merck oncolog product lynparza
fda label access cantor fitzgerald research
fda label access cantor fitzgerald research
fda label access cantor fitzgerald research
fda label access cantor fitzgerald research
indic usagepivot trial nctapprov datefor mainten treatment adult patient recurr epitheli ovarian fallopian tube primari periton cancer complet partial respons platinum-bas chemotherapi cancerind usagepivot trial nctapprov datemonotherapi treatment patient deleteri brca mutat germlin and/or somat associ advanc ovarian cancer treat two chemotherapi select patient therapi base fda-approv companion diagnost rubraca studi mainten treatment adult patient recurr epitheli ovarian fallopian tube primari periton cancer complet partial respons platinum-bas cancerind usagepivot trial nctapprov datefor treatment adult patient deleteri suspect deleteri germlin brca-mut gbrcam local advanc metastat breast cancer select patient therapi base fda-approv companion diagnost cancerind usagepivot trial nctapprov datefor mainten treatment adult patient deleteri suspect deleteri germlin somat brca-mut gbrcam sbrcam advanc epitheli ovarian fallopian tube primari periton cancer complet partial respons first-lin platinum-bas chemotherapi select patient gbrcam advanc epitheli ovarian fallopian tube primari periton cancer therapi base fda-approv companion diagnost mainten treatment adult patient recurr epitheli ovarian fallopian tube primari periton cancer complet partial respons platinum-bas treatment adult patient deleteri suspect deleteri germlin brca-mut gbrcam advanc ovarian cancer treat three prior line chemotherapi select patient therapi base fda-approv companion diagnost lynparza single-arm monotherapi patient deleteri suspect deleteri germlin brca mutat detect fda-approv test advanc ovarian cancer treat three prior line chemotherapi single-arm studi studi patient deleteri suspect deleteri gbrcam human epiderm growth factor receptor metastat breast cancer treat chemotherapi neoadjuv adjuv metastat set patient hormon receptor hr -posit breast cancer treat prior endocrin therapi consid inappropri endocrin therapi select patient therapi base fda-approv companion diagnost tablet formul capsul formul ovarian cancerbreast cancer merck oncolog product lynparza
exhibit upcom event parpi space
compani report present cantor fitzgerald research
productupcom timelinesncttri armspopulationeu approv decis metastat breast cancerphas polo data mutat metastat pancreat cancer whose diseas progress platinum base chemotherapyphas profound data abirateron acetatemetastat castration-resist prostat cancer mcrpc fail prior treatment new hormon agent homolog recombin repair gene mutationsphas data advanc figo stage iiib iv high grade serou endometrioid ovarian fallopian tube periton cancer treat standard treatment combin platinum-taxan chemotherapi bevacizumab concurr chemotherapi maintenancephas propel estim primari complet date april abiraterone-placebo abirateronemcrpc patient receiv prior cytotox chemotherapi new hormon agent nha mcrpc stagephas estim primari complet date octob olaparib-abirateron prednison enzalutamidemetastat castration-resist prostat cancer mcrpc unselect homolog recombin repair defect fail prior treatment one next-gener hormon agent nha chemotherapi phase avanova data bevacizumabwomen platinum-sensit epitheli ovarian fallopian tube primari periton cancerphas prima data treatment patient advanc ovarian cancer follow respons front-lin platinum-bas chemotherapyphas ovario data treatment patient advanc ovarian cancer follow respons front-lin platinum-bas chemotherapyphas jasper estimate primari complet date march high expressing-nsclc expressingniraparib inhibitor combin first-lin non-smal cell lung cancer nsclc submiss quadra cancer patient receiv three four previou chemotherapi regimenszejula niraparib lynparza olaparib merck oncolog product lynparza
exhibit upcom event parpi space cont
compani report present cantor fitzgerald research
productupcom timelinesncttri armspopulationphas estimate primari complet june ovarian cancer patient brca mutat fail two prior line therapyphas athena estimate primari complet decemb nivolumab-rucaparib iv placebo-or placebo nivolumab-or placebo iv placebofirst-lin mainten treatment newli diagnos patient advanc ovarian cancer complet platinum-bas chemotherapyphas estimate primari complet februari acet enzalutamid docetaxel brca mutant atm mutant inclus germlin somat mcrpc patient progress androgen-receptor ar -target therapi yet receiv chemotherapi castrate-resist settingphas estimate primari complet octob data present esmo submiss year-end brca mutat inclus germlin somat also enrol patient deleteri mutat homolog recombin hr repair gene includ atm mcrpc patient progress receiv one line taxane-bas chemotherapi one two line ar-target therapyphas atla estimate primari complet decemb complet data fall local advanc metastat bladder cancerphas ari initi earli nivolumab patient relaps brca wild-typ ovarian cancer patient local advanc metastat bladder carcinoma inelig treatment cisplatinphas javelin parp medley data avelumabpati local advanc metastat solid tumor includ nsclc tnbc hr breast cancer recurr platinum sensit ovarian cancer urotheli cancer uc crpcphase data dna repair defect mcrpc previous receiv taxane-bas chemotherapi progress least novel hormon agentphas javelin brca/atm data avelumabloc advanc metastat solid tumor ataxia telangiectasia mutat atm gene defectphas data enzalumatide-enzalumatid placebomen mcrpc system treatment initi document mcrcp phase javelin ovarian parp data avelumab talazoparib -chemotherapi talazoparib -chemotherapi bevacizumab patient previous untreat advanc ovarian cancertalzenna talazoparib rubraca rucaparib merck oncolog product lynparza
exhibit quarterli color parpi market
compani report present cantor fitzgerald research
quarterli earn transcriptslynparza mrk/azn zejula tsro rubraca lead parpi class new/tot prescript increas demand all-com label ovarian cancer emerg bc indic lead parpi gbrcam mbc sinc launch eu patient treat zejula nearli use ovarian cancer share parpi treat ovarian cancer patient share patient treat recurr mainten set women live ovarian cancer treat platinum yet experienc recurr vast major late initi parpi mainten follow chemo may elig recurr mainten treatment anticip cannib recurr market unlik begin year parpi penetr ovarian cancer mainten appear remain rel flat brca-mut patient receiv parpi mainten set rubraca share overal parpi market gross-to-net adjust lead parpi class new total prescript growth across region major use ovarian sinc launch patient treat zejula nearli use ovarian cancer lead share parpi treat patient women receiv parpi mainten recurr ovarian cancer continu expect major recurr ovarian cancer patient receiv parpi mainten time parpi penetr ovarian cancer mainten patient receiv avastin monotherapi mainten receiv mainten therapi brca patient receiv parpi mainten gross-to-net adjust lead parpi class new total prescript strong growth across region roll broader label ovarian cancer tablet breast indic share parpi use ovarian cancer new patient began treatment zejula parpi penetr recurr mainten ovarian cancer market anticip parpi recurr mainten opportun achiev penetr expect largest share year sinc decemb launch patient initi therapi rubraca elig patient mainten set treat parpi believ data impact mainten set modest patient treat rubraca prior parpi recent day patient test germlin brca gross-to-net adjust regain class leadership follow approv broader ovarian cancer label launch new mbc indic strong growth across region signific major sale ovarian cancer patient treat zejula evenli divid w/ w/o brca mutat expect increas zejula penetr recurr mainten popul yoy share parpi use ovarian cancer market total use ovarian cancer expect approach peak sale associ current eu ovarian label net revenu rang /eu ovarian cancer market opportun nearli new patient initi rubraca therapi gross-to-net adjust growth continu eu resurg driven approv launch tablet util evenli divid among patient w/ w/o brca mutat septemb zejula captur parpi market ovarian cancer gross-to-net adjust new patient initi therapi non-ovarian use consist rubraca sale gross-to-net adjust market lead parpi patient began treatment zejula half carri gbrcam share parpi patient june ovarian cancer patient brca test gross-to-net adjust adjust adjust merck oncolog product lynparza ovarian cancer
ovarian epitheli cancer fallopian tube cancer primari periton cancer form kind tissu cover ovari
line fallopian tube peritoneum cancer often advanc diagnosi new case present
stage diagnosi treat way typic ovarian cancer treat follow phase therapi
surgeri use first main primari treatment ovarian cancer goal find far cancer
spread remov much cancer bodi possibl
chemotherapi ovarian cancer patient receiv chemotherapi primari treatment surgeri adjuv
treatment certain case chemotherapi may given shrink cancer surgeri main type
chemotherapi drug use ovarian cancer platinum agent taxan chemotherapi drug differ
work one drug often use combin regimen
second-lin mainten therapi given delay diseas progress among patient tumor recurr
includ target therapi bevacizumab parpi olaparib rucaparib niraparib pazopanib tyrosin kinas
inhibitor possibl hormon therapi antiestrogen aromatas inhibitor etc
recent merck receiv fda approv lynparza first-lin mainten therapi brca-mut
advanc ovarian cancer make first regulatori approv parp inhibitor set approv base
also merck announc posit phase result trial lynparza patient relaps ovarian
cancer two line treatment merck astrazeneca plan discuss result fda present full
data upcom medic congress data could help support earlier use lynparza treatment
notabl upcom ovarian cancer data lynparza includ phase trial test effect lynparza
combin bevacizumab mainten treatment patient newly-diagnos advanc ovarian cancer
regardless brca statu result expect could present much-broad market opportun first-
line mainten set solidifi lynparza parpi leadership
ringley moor patel poli adp-ribos polymeras inhibitor manag ovarian cancer drug class review peer-review journal formulari manag
merck compani report transcript cantor fitzgerald research
lenvima lenvatinib oral avail tyrosin kinas inhibitor tki develop part
collabor eisai cover lenvima current approv
treatment patient local recurr metastat progress radioact iodine-refractori
combin everolimu treatment patient advanc renal cell carcinoma rcc
first-lin treatment patient unresect hepatocellular carcinoma/hcc approv
march merck eisai enter world-wide co-develop co-commerci agreement
lenvima agreement merck eisai develop commerci lenvima jointli
monotherapi combin merck therapi keytruda
merck record share product sale net cost sale commerci cost allianc revenu
expens incur co-develop includ studi evalu lenvima monotherapi share
equal two compani reflect expens
agreement provid eisai receiv associ achiev certain clinic
regulatori mileston achiev mileston associ sale lenvima
eisai record lenvima product sale global merck eisai share gross profit equal
merck compani report fda label eisai pipelin updat cantor fitzgerald research
accord merck lenvima attract partner keytruda across broad rang malign accord
agreement merck eisai jointli initi clinic studi evalu lenvima/keytruda combin
support potenti indic six type cancer endometri cancer nsclc hepatocellular carcinoma
head neck cancer bladder cancer melanoma well basket trial target multipl cancer type
note highlight program lenvima
merck compani report clinicaltri gov access cantor fitzgerald research
carcinoma second-lin combin therapi antibodi pembrolizumabest primari complet februari cell carcinoma first-lin combin therapi everolimu antibodi pembrolizumabest primari complet april us therapi antibodi pembrolizumab select solid tumor metastat endometri cancer metastat head neck cancer metastat melanoma metastat nsclc metastat renal cell carcinoma metastat urotheli carcinoma estimate primari complet februari appendix
ceo success remain top prioriti board
titl
kenneth frazier chairman board chief execut offic merck co inc mr frazier join compani
vice presid gener counsel secretari compani joint ventur astra ab becam vice
presid public affair also name assist gener counsel mr frazier
promot gener counsel merck serv presid global human health merck sale
market divis mr frazier becam presid merck appoint ceo member merck
board director januari becam chairman board decemb prior join merck mr frazier
partner philadelphia law firm drinker biddl reath sit board phrma weill cornel
medicin exxon mobil corpor cornerston christian academi philadelphia pa also member
american academi art scienc busi council council american law institut american
bar associ mr frazier receiv bachelor degre pennsylvania state univers hold
execut vice presid
execut vice presid presid merck manufactur divis
global servic chief
execut vice presid global servic chief financi offic merck co inc
execut vice presid chief financi offic merck co inc
corpor vice presid presid baxter medic product
corpor vice presid chief financi offic baxter healthcar treasur baxter healthcar
director corpor plan compani assist treasur variou financi posit
compani
compani report present cantor fitzgerald research
overview landscap
exhibit approv indic keytruda
merck compani report fda label cantor fitzgerald research
indic usagepivot trial nctapprov datefor treatment patient unresect metastat adjuv treatment patient melanoma involv lymph node follow complet resect combin pemetrex platinum chemotherapi first-lin treatment patient metastat nonsquam nsclc egfr genom tumor combin carboplatin either paclitaxel nabpaclitaxel first-lin treatment patient metastat squamou singl agent first-lin treatment patient metastat nsclc whose tumor high express tumor proport score tp determin fda-approv test egfr genom tumor singl agent treatment patient metastat nsclc whose tumor express tp determin fda-approv test diseas progress platinum-contain chemotherapi patient egfr genom tumor aberr diseas progress fda-approv therapi aberr prior receiv treatment patient recurr metastat hnscc diseas progress platinum-contain chemotherapi treatment adult pediatr patient refractori chl relaps prior line therapi treatment adult pediatr patient refractori pmbcl relaps prior line therapi limit use keytruda recommend treatment patient pmbcl requir urgent cytoreduct treatment patient local advanc metastat urotheli carcinoma elig cisplatin-contain chemotherapi whose tumor express combin posit score patient elig platinum-contain chemotherapi regardless statu treatment patient local advanc metastat urotheli carcinoma diseas progress follow platinum-contain chemotherapi within month neoadjuv adjuv treatment platinum-contain treatment adult pediatr patient unresect metastat microsatellit instability-high msi-h mismatch repair defici -solid tumor progress follow prior treatment satisfactori altern treatment option colorect cancer progress follow treatment fluoropyrimidin oxaliplatin irinotecan limit use safeti effect keytruda pediatr patient msi-h central nervou system cancer treatment patient recurr local advanc metastat gastric gastroesophag junction adenocarcinoma whose tumor express combin posit score determin fda-approv test diseas progress two prior line therapi includ fluoropyrimidine- platinum-contain chemotherapi appropri therapi treatment patient recurr metastat cervic cancer diseas progress chemotherapi whose tumor express determin fda-approv test treatment patient previous treat sorafenib treatment adult pediatr patient recurr local advanc metastat merkel cell carcinoma approv acceler approv base tumor respons rate durabl respons continu approv indic may conting upon verif descript clinic benefit confirmatori trial label approv treatment patient unresect metastat melanoma diseas progress follow ipilimumab braf mutat posit braf control trial melanoma patient previous treat ipilimumab control trial melanoma patient nave treatment ipilimumab label approv combin pemetrex carboplatin first-lin treatment patient metastat nonsquam nsclc label approv treatment patient local advanc metastat urotheli carcinoma elig cisplatin-contain chemotherapi urotheli carcinomamelanomanon-smal cell lung cancer nsclc head neck squamou cell cancer hnscc classic hodgkin lymphoma chl primari mediastin larg b-cell lymphoma pmbcl microsatellit instability-high cancergastr cancercerv cancerhepatocellular carcinoma merkel cell carcinoma mcc overview landscap
exhibit approv indic opdivo
bristol-my squibb compani report fda label cantor fitzgerald research
indic usagepivot trial nctapprov datepati braf wild-typ unresect metastat melanoma singl braf mutation-posit unresect metastat melanoma singl agent unresect metastat melanoma combin ipilimumab melanoma lymph node involv metastat diseas undergon complet resect adjuv metastat non-smal cell lung cancer progress platinum-bas chemotherapi patient egfr genom tumor aberr diseas progress fda-approv therapi aberr prior receiv opdivo metastat small cell lung cancer progress platinum-bas chemotherapi least one line therapi advanc renal cell carcinoma receiv prior antiangiogen intermedi poor risk previous untreat advanc renal cell carcinoma combin patient classic hodgkin lymphoma relaps progress -autolog hematopoiet stem cell transplant hsct brentuximab vedotin line system therapi includ autolog hsct recurr metastat squamou cell carcinoma head neck diseas progress platinum-bas local advanc metastat urotheli carcinoma -have diseas progress follow platinum-contain chemotherapi -have diseas progress within month neoadjuv adjuv treatment platinum-contain chemotherapi pediatr year older patient msi-h dmmr metastat colorect cancer progress follow treatment fluoropyrimidin oxaliplatin irinotecan singl agent combin ipilimumab hepatocellular carcinoma previous treat sorafenib approv acceler approv base progression-fre surviv continu approv indic may conting upon verif descript clinic benefit confirmatori trial approv acceler approv base overal respons rate durat respons continu approv may conting upon verif descript clinic benefit confirmatori trial label approv treatment patient unresect metastat melanoma diseas progress follow ipilimumab braf mutat posit braf inhibitor label approv singl agent patient diseas progress follow ipilimumab braf mutat posit braf inhibitor label approv combin ipilimumab patient braf wild-typ melanoma label approv metastat squamou non-smal cell lung cancer patient progress platinum-bas chemotherapi label approv classic hodgkin lymphoma relaps progress autolog hematopoiet stem cell transplant hsct posttransplant brentuximab vedotin label approv adult pediatr year older patient microsatellit instability-high msi-h mismatch repair defici dmmr metastat colorect cancer progress follow treatmentwith fluoropyrimidin oxaliplatin irinotecan squamou cell carcinoma head neck scchn urotheli carcinomamicrosatellit instability-high msi-h mismatch repair defici dmmr metastat colorect cancerhepatocellular carcinomaunresect metastat melanomaadjuv treatment melanomametastat non-smal cell lung cancer nsclc small cell lung cancer sclc advanc renal cell carcinomaclass hodgkin lymphoma overview landscap
exhibit approv indic tecentriq
roch astrazeneca compani report fda label cantor fitzgerald research
roch astrazeneca compani report fda label cantor fitzgerald research
roch astrazeneca compani report fda label cantor fitzgerald research
indic usagepivot trial nctapprov datefor treatment patient local advanc metastat urotheli carcinoma -are elig cisplatin-contain chemotherapi whose tumor express stain tumor-infiltr immun cell ic cover tumor area determin fda-approv test -are elig platinum-contain chemotherapi regardless statu -have diseas progress follow platinum-contain chemotherapi within month neoadjuv adjuv chemotherapi cohort cohort combin bevacizumab paclitaxel carboplatin firstlin treatment patient metastat non-squam nsclc egfr genom tumor aberr treatment patient metastat nsclc diseas progress follow platinum-contain chemotherapi patient egfr genom tumor aberr diseas progress fda-approv therapi aberr prior receiv tecentriq approv acceler approv base tumor respons rate durat respons continu approv indic may conting upon verif descript clinic benefit confirmatori trial label approv treatment patient local advanc metastat urotheli carcinoma diseas progress follow platinum-contain chemotherapi diseas progress within neoadjuvc adjuv treatment platinum-contain chemotherapi label approv local advanc metastat urotheli carcinoma elig cisplatin-contain chemotherapi diseas progress follow platinum-contain chemotherapi orwithin month neoadjuv adjuv chemotherapi local advanc metastat urotheli carcinomametastat non-smal cell lung cancerind usagepivot trial nctapprov dateloc advanc metastat urotheli carcinoma -have diseas progress follow platinum-contain chemotherapi -have diseas progress within month neoadjuv adjuv treatment platinum-contain chemotherapi studi stage non-smal cell lung cancer nsclc whose diseas progress follow concurr platinum-bas chemotherapi radiat approv acceler approv base tumor respons rate durat respons continu approv indic may conting upon verif descript clinic benefit inconfirmatori trial urotheli carcinomanon-smal cell lung cancerind usagepivot trial nctapprov dateadult pediatr patient year older metastat merkel cell carcinoma mcc javelin merkel patient local advanc metastat urotheli carcinoma uc -have diseas progress follow platinum-contain chemotherapi -have diseas progress within month neoadjuv adjuv treatment platinum-contain chemotherapi uc cohort javelin solid approv acceler approv base tumor respons rate durat respons continu approv may conting upon verif descript clinic benefit confirmatori trial metastat merkel cell carcinomaloc advanc metastat urotheli carcinoma overview landscap eu
exhibit approv eu indic keytruda
merck compani report ema cantor fitzgerald research
indic usagepivot trial approv datemelanomaa monotherapi treatment advanc unresect metastat melanoma monotherapi adjuv treatment adult stage melanoma lymph node involv undergon complet cell lung cancer nsclc monotherapi first-lin treatment metastat non-smal cell lung carcinoma nsclc adult whose tumour express tumour proport score tp egfr posit tumour combin pemetrex platinum chemotherapi first-lin treatment metastat non-squam nsclc adult whose tumour egfr posit monotherapi treatment local advanc metastat nsclc adult whose tumour express tp receiv least one prior chemotherapi regimen patient egfr posit tumour mutat also receiv target therapi receiv hodgkin lymphoma chl monotherapi treatment adult patient relaps refractori classic hodgkin lymphoma chl fail autolog stem cell transplant asct brentuximab vedotin bv transplant-inelig fail carcinomaa monotherapi treatment local advanc metastat urotheli carcinoma adult receiv prior platinum-contain monotherapi treatment local advanc metastat urotheli carcinoma adult elig cisplatin-contain chemotherapi whose tumour express combin posit score head neck squamou cell cancer hnscc monotherapi treatment recurr metastat head neck squamou cell carcinoma hnscc adult whose tumour express tp progress platinum-contain restrict indic cisplatin-inelig urotheli carcinoma patient exclud patient whose tumour express combin posit score base review interim analysi data independ data monitor committe idmc studi keynote- treatment melanoma overview landscap eu
exhibit approv eu indic opdivo
bristol-my squibb compani report ema cantor fitzgerald research
indic usagepivot trial approv datea monotherapi combin ipilimumab treatment advanc unresect metastat melanoma adult rel nivolumab monotherapi increas progression-fre surviv overal surviv os combin nivolumab ipilimumab establish patient low tumour express adjuv treatment melanomaa monotherapi adjuv treatment adult melanoma involv lymph node metastat diseas undergon complet monotherapi treatment local advanc metastat non-smal cell lung cancer prior chemotherapi sq nonsq juli monotherapi treatment advanc renal cell carcinoma prior therapi combin ipilimumab first-lin treatment adult patient intermediate/poor-risk advanc renal cell monotherapi treatment adult patient relaps refractori classic hodgkin lymphoma autolog stem cell transplant asct treatment brentuximab monotherapi treatment recurr metastat squamou cell cancer head neck adult progress platinum-bas monotherapi treatment local advanc unresect metastat urotheli carcinoma adult failur prior platinum-contain extens indic includ treatment local advanc metastat squamou non-smal cell lung cancer nsclc prior chemotherapi adult extens indic includ treatment monotherapi local advanc metastat non-squam nsclc prior chemotherapi adult extens indic includ treatment combin ipilimumab advanc unresect metastat melanoma adult base interim data studi final csr studi opdivo monotherapi indic treatment advanc unresect metastat melanoma adult classic hodgkin lymphomamelanomasquam cell carcinoma head neck scchn urotheli carcinomametastat non-smal cell lung cancer nsclc advanc renal cell overview landscap eu
exhibit approv eu indic tecentriq
roch astrazeneca compani report fda label cantor fitzgerald research
roch astrazeneca compani report fda label cantor fitzgerald research
roch astrazeneca compani report fda label cantor fitzgerald research
indic usagepivot trial approv datea monotherapi treatment adult patient local advanc metastat urotheli carcinoma uc prior platinum-contain chemotherapi consid cisplatin monotherapi treatment adult patient local advanc metastat non-smal cell lung cancer nsclc prior chemotherapi patient egfr activ mutat alk-posit tumour mutat also receiv target therapi receiv tecentriq oak advanc metastat urotheli carcinomametastat non-smal cell lung cancer nsclc indic usagepivot trial approv datea monotherapi treatment local advanc stage unresectablenon-smal cell lung cancer nsclc adult whose tumour express tumour cell whose diseas progress follow platinum-bas chemoradi cell lung cancerind usagepivot trial approv datea monotherapi treatment adult patient metastat merkel cell carcinoma mcc merkel cell carcinoma overview landscap japan
exhibit approv japan indic keytruda
merck compani report japan pmda cantor fitzgerald research
indic usagepivot trial approv datemelanomafor treatment unresect stage iii/iv malign adjuv therapi januari treatment patient posit unresect recurr advanc non-smal cell lung cancer first-lin treatment patient posit unresect recurr advanc non-smal cell lung cancer second-lin combin pemetrex platinum-bas chemotherapi cisplatin carboplatin first-lin treatment unresect advanced/recurr nonsquam nsclc regardless januari combin carboplatin paclitaxel nab-paclitaxel first-lin treatment unresect advanced/recurr squamou nsclc regardless januari first-lin treatment tumor proport score tp unresect advanced/recurr januari hodgkin lymphoma chl treatment relaps refractori classic hodgkin carcinomafor treatment unresect urotheli cancer progress cancer monotherapi treatment advanced/recurr msi-h solid tumor progress chemotherapi refractori intoler standard januari instability-high cancernon-smal cell lung cancer nsclc overview landscap japan
exhibit approv japan indic opdivo
bristol-my squibb compani report japan pmda cantor fitzgerald research
indic usagepivot trial approv datefor treatment unresect malign melanoma patient previous untreat chemotherapi patient previous treat combin therapi ipilimumab patient previous untreat adjuv treatment treatment unresect advanc recurr non-small-cel lung treatment unresect metastat renal cell combin therapi ipilimumab unresect metastat renal cell carcinoma previous untreat treatment relaps refractori classic hodgkin treatment recurr metastat head neck treatment unresect advanc recurr gastric cancer progress treatment unresect advanc recurr malign pleural mesothelioma progress collabor agreement bristol-my squibb expand territori right develop commerci opdivo nivolumab global except japan korea taiwan ono retain right compound new dosag indic treatmentof unresect melanoma malign pleural mesotheliomaadjuv melanomametastat non-smal cell lung cancer nsclc melanomaadvanc renal cell carcinomaclass hodgkin lymphomahead neckgastr cancer overview landscap japan
exhibit approv japan indic tecentriq
roch astrazeneca compani report fda label cantor fitzgerald research
exhibit approv japan indic imfinzi
roch astrazeneca compani report fda label cantor fitzgerald research
exhibit approv japan indic bavencio
roch astrazeneca compani report fda label cantor fitzgerald research
indic usagepivot trial approv datefor treatment unresect advanc recurr non-small-cel lung combin carboplatin paclitaxel bevacizumab genet recombin treatment previous untreat unresect advanc recurr non-squam non-smal cell lung cancer member roch group roch hold chugai outstand share base strateg allianc agreement metastat non-smal cell lung cancer nsclc indic usagepivot trial approv datea mainten therapi definit chemoradi therapi crt locally-advanc stage unresect non-smal cell lung cancer nsclc pacif cell lung cancerind usagepivot trial approv datefor treatment unresect merkel cell carcinoma javelin merkel merkel cell carcinoma merck oncolog product truda current perform
exhibit histor color keytruda sale
merck compani transcript cantor fitzgerald research
quarterli earn transcriptsusag tumor type usag tumor type internationaladdit head indic major use lung cancer clear market leader renal continu strong futur growth prospectsglob growth driven primarili higher use nsclc see strong uptak sqnsclc ex-u market lung key driver growth mostli due uptak monotherapi indic high express septemb launch truda metastat melanoma head indic lung largest tumor type vs tumor type use lung continu increas driven uptak monotherapi indic follow reimburs approv approv combo earli septemb tripl elig market lead i-o new patient start total patient volum growth driven higher use first-lin nonsquam nsclc without egfr express beyond lung truda leadership posit head neck bladder msi-high msi-high indic eu japan lung major revenu follow melanoma -lead i-o new patient start look indic combin current captur new patient start exclud egfr -accord data enabl truda becom soc squamou nsclc truda abl repres nsclc patient os head indic outsid major util metastat melanoma lung lung cancer repres major sale major eu market new patient start truda i-o truda remain leader metastat lung cancer truda remain lead i-o head neck bladder cancer continu use extens metastat melanoma also gain traction msi-high test rate continu increas across mani differ tumor type head bladderremaind indic major eu sale remain melanoma lung becom growth driver truda continu lead new patient start across nearli indic rema lead treatment option across i-o non i-o therapi metastat lung cancer addit leadership melanoma recent approv addit tumor type key market includ lung bladder cancer expect drive increment head indic continu maintain leadership posit class melanoma see greater contribut lung cancer earli perform japan also strong new patient start truda i-o agent across indic across lung cancer nearli one three new lung cancer patient start truda make prescrib treatment new metastat lung cancer nsclc leader nsclc new patient start overal share approv first- second-lin lung cancer countri europ merck seen strong uptak first- second-lin lung japan follow launch seen strong adopt truda monotherapi high express popul quickli becom standard care set truda leader term market share first-lin lung cancer outsid lung cancer truda continu lead therapi metastat melanoma mani market around world merck also seen strong launch across bladder cancer head neck cancer classic hodgkin lymphoma well earli interest head indic outsid melanoma continu drive major truda sale nsclc one four patient treat truda second-lin lung truda share pretti stabl time truda prescrib product first-lin lung set second-lin lung share rel stabl merck work grow share expand indic posit patient merck oncolog product emend
emend aprepit capsul oral suspens emend fosaprepit inject use
medicin treat nausea vomit patient six month age older prevent nausea vomit
caus certain anti-canc chemotherapi medicin
initi approv emend capsul oral suspens emend inject
loe emend inject ip expir septemb eu ip expir japan ip expir
global sale yoy increas includ sale
global sale yoy increas includ unfavor effect foreign exchang
larg reflect higher price partial off-set volum declin japan includ sale
sale
februari merck announc fda approv supplement new drug applic
single-dos emend inject prevent delay nausea vomit adult receiv
initi repeat cours moder emetogen chemotherapi approv emend
inject first intraven single-dos receptor antagonist approv highli
emetogen chemotherapi moder emetogen chemotherapi
global sale yoy decreas reflect unfavor effect foreign exchang
partial off-set higher price volum growth eu includ sale
sale
cantor expect rapid gener eros begin driven loe eu japan
elig month pediatr exclus
merck compani report cdc gov
temodar temozolomid market temod outsid chemotherapi treatment certain type
loe gener competit begin august patents/exclus period otherwis expir
februari eu loe
major gener impact occur temodar compar temodar gener world-wide
sale fell sale affect eu loe sinc loe temodar fell
sale sale sale
cantor expect continu mid-single-digit sale eros driven sale
gardasil papillomaviru quadrival type vaccin recombin gardasil
papillomaviru vaccin recombin vaccin help prevent certain cancer diseas caus certain
type hpv
loe gardasil ip expir june eu ip expir japan ip expir
loe gardasil ip expir june eu ip expir patent spc japan ip n/a
gardasil hpv vaccin avail gardasil earlier version hpv vaccin longer
avail previou competitor glaxosmithklin cervarix human papillomaviru bival type
vaccin recombin approv pull market gsk due low market
demand vaccin gardasil protect type hpv accord cdc licensur
decemb decemb dose gardasil distribut licensur june
decemb dose gardasil distribut
cantor expect high single-digit sale growth driven primarili launch uptak increas
demand market china eu moder growth think coverag level
 current level could grow someth closer routin recommend adolesc vaccin
expect sale growth high mid-singl digit
elig month pediatr exclus
merck compani report cdc gov
papillomaviru hpv viru affect men women commonli teen earli accord
cdc peopl get hpv infect point live peopl includ teen becom infect
hpv year peopl current infect hpv infect caus cervic vagin vulvar cancer
women penil cancer men oropharyng anal cancer well genit wart men women
gardasil target hpv type caus cervic cancer major hpv-associ cancer men
women also target hpv type caus genit wart gardasil protect well five
addit cancer caus type hpv caus cervic cancer addit five type mostli
benefit femal small percentag hpv-associ cancer male due type hpv
advisori committe immun practic acip recommend routin hpv vaccin girl boy age
octob acip updat hpv vaccin recommend regard dose schedul previous vaccin
approv administr three-dos seri interv month octob gardasil fda
approv use two-dos seri girl boy age year acip recommend schedul
although merck seen declin sale due on-going impact transit three-dos regimen
two-dos regimen partial off-set higher price well increas patient start
exhibit acip recommend hpv vaccin
merck compani report cdc gov
accord nation immun survey-teen nis-teen coverag increas dose
hpv vaccin hpv vaccin coverag increas averag percentag point annual
sinc think hpv vaccin coverag level could grow compar routin
exhibit estim vaccin coverag select vaccin dose among adolesc age year nation immun
 vaccin vaccinehistori varicella histori varicella vaccin vaccin varicella diseas receipt varicella vaccin hpv human papillomaviru menacwi quadrival meningococc conjug vaccin mmr measl mump rubella vaccin tdap tetanu toxoid reduc diphtheria toxoid acellular pertussi vaccin statist signific differ compar nis-teen estim receiv dose follow appli receiv dose first dose receiv birthday interv first second dose month minu day absolut minimum interv first second dose total ci vaccin februari
world-wide sale yoy increas driven primarili higher sale attribut borrow
cdc pediatr vaccin stockpil higher demand intern market particularli china due
on-going launch eu
april china food drug administr approv gardasil use girl women age octob
fda approv expand age indic use women men age prevent certain
cancer diseas caus nine hpv type cover vaccin
world-wide sale yoy increas driven primarili higher sale asia pacif region particularli
china reflect continu uptak sinc launch well volum growth certain eu market partial off-set declin
 reflect on-going impact transit three-dos regimen two-dos regimen recommend
acip decemb partial off-set higher price
world-wide sale yoy increas driven primarili higher sale asia pacif region particularli
china reflect continu uptak sinc launch well volum growth certain eu market sale declin reflect
on-going impact transit three-dos regimen two-dos regimen
world-wide sale yoy increas driven primarili higher sale eu result termin
spmsd joint ventur well higher demand asia pacif due part launch china partial off-set lower
sale reflect time public sector purchas merck made request borrow dose gardasil
cdc pediatr vaccin stockpil merck decis borrow dose cdc driven part temporari shutdown
result cyber-attack occur june overal higher demand expect result borrow
merck revers sale relat borrow dose recogn correspond liabil merck subsequ replenish
nearli half dose borrow stockpil net effect borrow subsequ partial replenish
reduct sale merck also experienc impact transit three-dos vaccin regimen
two-dos vaccin regimen howev increas patient start help off-set neg effect transit
merck compani report cdc gov
merck compani report cdc gov
histor sale salesintern approv decemb merck sanofi termin equally-own joint ventur spmsd develop market vaccin europ vaccin sale includ sale merck vaccin eu market previous part spmsd joint ventur whereassal period prior suppli sale spmsd includ vaccin sale period prior increment vaccin sale result termin spmsd joint ventur relat gardasil/gardasil merck borrow dose gardasil cdc pediatr vaccin stockpil driven part temporari shutdown result cyber-attack occur june well overal higher demand expect result borrow merck revers sale relat toth borrow dose reduc revenu merck replenish portion borrow dose net effect borrow subsequ partial replenish reduct sale merck anticip replenish remain borrow dose februari
proquad m-m-r ii varivax asset merck vaccin portfolio
proquad pediatr combin vaccin help protect measl mump rubella varicella
essenti combo equival compon vaccin m-m-r ii varivax
m-m-r ii vaccin help protect measl mump rubella
varivax vaccin help prevent chickenpox varicella
prevent measl mump rubella varicella advisori committe immun practic acip
recommend two-dos vaccin schedul childhood first dose administ age month
second dose age year
exhibit acip recommend proquad m-m-r ii varivax
merck compani report merckvaccin com cdc gov
exhibit histor revenu product
merck compani report cantor fitzgerald research
commentaryhigh sale reflect increas volum driven part measl outbreak higher price higher demand price higher price volum volum growth intern market particularli eu higher volum price volum growth intern market esp certain eu market higher volum price volum growth certain eu market higher volum price volum growth certain eu market total commentaryhigh demand result measl outbreak higher price higher demand result measl outbreakhigh eu sale result termin spmsd joint ventur volum growth sever intern market volum growth sever intern market -total commentaryhigh volum certain emerg market higher price partial off-set lower volum higher sale reflect effect public sector purchas higher price partial off-set lower demand well volum growth brazil reflect time govern tender lower volum brazil due loss govern tender lower sale reflect lower demand partial off-set higher price partial off-set higher eu sale result termin spmsd joint ventur volum growth intern market along higher price volum growth intern market along higher price primarili reflect volum declin turkey due loss govern tender partial off-set volum growth latin america proquad/m-m-r ii/varivax total ii/varivax ii/varivax iivarivax februari
pneumovax pneumococc vaccin polyval vaccin indic activ immun prevent
pneumococc diseas caus serotyp contain vaccin
pneumovax approv use person year
age older person age year increas risk pneumococc diseas
pneumococc diseas group ill caus bacterium streptococcu pneumonia pneumonia
also known pneumococcu includ invas infect bacteremia sepsi mening well
non-invas infect pneumonia otiti media known pneumococc
serotyp strain type caus diseas
current two type pneumococc vaccin avail
cantor expect stabl low mid-single-digit sale growth given way pneumovax prevnar
schedul per advisori committe immun practic acip recommend one
erod other sale see near medium-term threat pneumovax
merck sanofi establish equally-own joint ventur market vaccin europ collabor develop combin vaccin distribut europ joint ventur
expir compani integr respect eu vaccin busi oper
merck compani report cdc gov
global sale yoy decreas driven primarili lower sale reflect lower
demand partial off-set higher price foreign exchang unfavor affect global sale perform
sale rel flat first nine month higher price off-set lower volum
sale sale
global sale yoy increas driven primarili higher volum price
 well higher volum eu foreign exchang favor affect global sale perform
sale sale
global sale yoy increas driven primarili volum growth intern
market foreign exchang favor affect global sale perform sale
 sale
global sale yoy increas driven primarili higher demand price
 well higher sale eu result termin spmsd joint ventur
sale sale
merck sanofi establish equally-own joint ventur market vaccin europ collabor develop combin vaccin distribut europ joint ventur
expir compani integr respect eu vaccin busi oper
exhibit vaccin accord acip children
cdc gov cantor fitzgerald research
patient w/ certainmed dose month month month w/o certain medic condit unvaccin receiv incomplet seri dose unvaccin receiv incomplet servi dose second dose give least week dose receiv dose none given month dose least week seri complet chronic heart diseas chronic lung diseas diabet mellitu cerebrospin fluid leak cochlear implant sickl cell diseas hemoglobinopathi congenit acquir asplenia splenic dysfunct hiv infect chronic renal failur nephrot syndrom diseas associ treatment immunosuppress drug radiat therapi includ malign neoplasm leukemia lymphoma hodgkin diseas solid organ transplant congenit dose unvaccin receiv incomplet servi dose second dose give least week dose receiv dose none given month dose seri complet first dose least week prior dose second dose least year first cerebrospin fluid leak cochlear implant sicklecel diseas hemoglobinopathi congenit acquir asplenia splenic dysfunct hiv infect chronic renal failur nephrot syndrom diseas associ treatment immunosuppress drug radiat therapi includ malign neoplasm leukemia lymphoma hodgkin diseas solid organ transplant congenit immunodefici chronic heart diseas chronic lung diseas diabet mellitu alcohol chronic liver diseas cigarett dose receiv dose administ give recommend dose dose alreadi given earlier childhood least week dose receiv dose administ give recommend dose patient dose first dose given least week prior dose second dose least year alreadi given earlier certain medic condit patient w/ certainmed dose month month month w/o certain medic condit unvaccin receiv incomplet seri dose unvaccin receiv incomplet servi dose second dose give least week dose receiv dose none given month dose least week seri complet chronic heart diseas chronic lung diseas diabet mellitu cerebrospin fluid leak cochlear implant sickl cell diseas hemoglobinopathi congenit acquir asplenia splenic dysfunct hiv infect chronic renal failur nephrot syndrom diseas associ treatment immunosuppress drug radiat therapi includ malign neoplasm leukemia lymphoma hodgkin diseas solid organ transplant congenit dose unvaccin receiv incomplet servi dose second dose give least week dose receiv dose none given month dose seri complet first dose least week prior dose second dose least year first cerebrospin fluid leak cochlear implant sicklecel diseas hemoglobinopathi congenit acquir asplenia splenic dysfunct hiv infect chronic renal failur nephrot syndrom diseas associ treatment immunosuppress drug radiat therapi includ malign neoplasm leukemia lymphoma hodgkin diseas solid organ transplant congenit immunodefici chronic heart diseas chronic lung diseas diabet mellitu alcohol chronic liver diseas cigarett dose receiv dose administ give recommend dose dose alreadi given earlier childhood least week dose receiv dose administ give recommend dose patient dose first dose given least week prior dose second dose least year alreadi given earlier certain medic condit merck vaccin product pneumovax cont
exhibit vaccin accord acip adult
cdc gov cantor fitzgerald research
patient dose least week dose cerebrospin fluid leak orcochlear implant sickl cell diseas hemoglobinopathi congenit acquir asplenia congenit acquir immunodefici hiv infect chronic renal failur nephrot syndrom leukemia lymphoma hodgkin diseas gener malign latrogen immunosuppress diseas requir treatment immunosuppress drug includ long-term system corticosteroid radiat therapi solid organ transplant multipl dose first dose least week dose second dose least year first smoke havenot previous receiv dose alcohol chronic heart diseas chronic liver diseas chronic lung diseas diabet dose least year prior dose least year prior dose adult receivedon two dose age receiv one final dose previous receiv recommend pneumococcalvaccin certain medic condit smoke merck vaccin product rotateq
rotateq rotaviru vaccin live oral pentaval vaccin indic prevent rotaviru
gastroenter caus type rotateq approv use infant six week week
age
advisori committe immun practic acip recommend routin vaccin infant
rotaviru vaccin express prefer either two avail rotaviru vaccin product
merck rotateq glaxosmithklin cover rotarix
rotateq given three dose age two month four month six month rotateq reassort
rotarix given two dose age two month four month rotarix deriv singl common
strain human rotaviru
world organ recommend rotaviru vaccin includ nation
loe ip expir februari ip expir eu japan
cantor expect stabl low single-digit growth awar pipelin asset competitor
could potenti affect sale neg near medium term
merck compani report world health organ acip guidelin
merck compani report acip guidelin
world-wide sale yoy increas includ unfavor effect foreign exchang
driven primarili launch china higher volum price
world-wide sale yoy increas includ favor effect foreign exchang
driven primarili higher sale reflect time public sector purchas
world-wide sale yoy declin includ favor effect foreign exchang
driven primarili lower sale reflect time public sector purchas
world-wide sale yoy increas driven primarili higher sale eu result
termin spmsd joint ventur
merck sanofi establish equally-own joint ventur market vaccin europ collabor develop combin vaccin distribut europ joint ventur
expir compani integr respect eu vaccin busi oper
zostavax zoster vaccin live live attenu viru vaccin indic prevent herp zoster shingl
individu year age older
loe ip expir eu ip expir japan ip n/a
world-wide sale yoy declin driven lower volum market particularli
 sale sale
world-wide sale yoy declin foreign exchang favor affect global sale perform
sale declin larg attribut lower demand reflect approv competitor
vaccin receiv preferenti recommend zostavax cdc acip octob
prevent shingl sale sale
world-wide sale yoy declin includ favor effect foreign exchang sale
declin larg attribut lower demand reflect approv competitor vaccin
zostavax cdc acip octob prevent shingl sale
cantor expect continu signific high double-digit sale eros due approv competitor
product glaxosmithklin shingrix receiv preferenti recommend advisori
committe immun practic octob addit expect eros ex-u
market shingrix approv europ japan march
bridion sugammadex inject indic revers effect induc two type neuromuscular block
agent rocuronium bromid vecuronium bromid adult undergo surgeri neuromuscular block drug
muscular relax use paralyz vocal cord patient requir artifici airway breath tube
surgeri also use prevent patient move surgeri receiv gener anesthesia
benefit bridion clinic studi return recoveri time faster overal patient receiv bridion compar
patient receiv differ drug neostigmin revers neuromuscular blockad patient recov within
minut routin use bridion
exhibit bridion vs neostigmin revers agent neuromuscular blockad reappear moder blockad
initi approv decemb approv eu
loe loe januari pend eu ip expir japan ip expir
expir januari without patent term extens elig pediatr exclus
merck compani report bridion fda label fda gov
cantor expect continu double-digit sale growth driven primarili sale gener
eros begin eu follow gener eros japan
global sale yoy increas includ neg effect foreign exchang
driven volum growth certain eu market bridion continu experi strong
demand recent launch china repres opportun
sale sale
global sale yoy increas includ favor effect foreign
exchang reflect volum growth market particularli eu
sale sale
color merck neuromuscular blockad market continu grow increas
robot minim invas surgic procedur bridion continu gain market share
revers agent choic
global sale yoy increas includ favor effect foreign
exchang primarili reflect volum growth certain eu market
sale sale
merck compani report cantor fitzgerald research
noxafil posaconazol azol antifung agent prevent invas fungal infect
loe ip expir juli eu ip expir japan ip n/a
world-wide sale yoy increas includ unfavor effect foreign exchang primarili
reflect higher demand well volum growth certain eu market china
world-wide sale yoy increas includ favor effect foreign exchang primarili
reflect higher demand price well volum growth certain eu market
world-wide sale yoy increas includ favor effect foreign exchang primarili
reflect higher demand price well volum growth certain eu market
world-wide sale yoy increas primarili reflect higher demand price well
volum growth eu
settlement actavi laboratori teva teva neutral wherebi actavi launch gener version prior expiri
patent pediatr exclus certain condit
settlement roxan laboratori wherebi roxan launch gener version prior expiri patent certain
settlement endo neutal wherebi launch gener version januari earlier
certain condit
februari file lawsuit freseniu kabi usa cover respect freseniuss applic fda seek
pre-pat expiri approv sell gener version noxafil
fda grant tent approv freseniu kabi usa posaconazol note januari fda
disclos paragraph iv certif anda file posaconazol
march file lawsuit neutral respect applic fda seek pre-pat expiri
approv sell gener version noxafil
cantor expect rapid gener eros begin driven eu loe
invanz ertapenem sodium iv im intramuscular penem antibacteri indic adult patient pediatr
patient three month age older treatment certain infect
loe ip expir novemb eu ip expir japan ip n/a
global sale yoy declin includ unfavor effect foreign exchang driven
primarili lower volum sale sale
global sale yoy declin sale sale
global sale yoy increas includ favor effect foreign exchang
sale sale
global sale yoy increas driven primarili higher sale reflect higher price
partial off-set lower demand well higher demand brazil sale
cantor expect signific double-digit sale declin driven primarili decreas sale result
merck compani report fda orang book
cubicin daptomycin inject iv lipopeptid antibiot indic treatment
complic skin skin structur infect csssi adult pediatr patient year age
staphylococcu aureu bloodstream infect bacteremia adult patient includ right-sid
infect endocard
staphylococcu aureu bloodstream infect bacteremia pediatr patient year age
loe loe occur june eu loe occur earli
global sale yoy increas
global sale yoy declin
global sale yoy increas
global sale yoy declin driven rapid substanti declin
cantor expect mid-single-digit sale eros major gener eros taken
place
cancida caspofungin acet echinocandin antifung sold primarili outsid
loe loe august eu loe april japan ip expir
global sale yoy declin includ unfavor effect foreign exchang
driven gener competit certain eu market
global sale yoy declin includ favor effect foreign exchang
driven primarili gener competit certain eu market
global sale yoy declin includ favor effect foreign exchang
driven primarili gener competit certain eu market
global sale yoy declin driven primarili gener competit certain eu
market sale sale
global sale yoy declin reflect unfavor effect foreign exchang
price declin eu off-set higher volum certain emerg market particularli china
sale sale
cantor expect continu double-digit gener eros eu loe addit eros begin
japan loe
lost august due patent litig settlement reach freseniu kabi
merck compani report evaluatepharma
primaxin imipenem cilastatin sodium iv anti-bacteri product broad-spectrum beta-lactam
contain combin imipenem penem antibacteri cilastatin renal dehydropeptidas
inhibitor indic treatment seriou infect caus design suscept bacteria
infect bacteri septicemia bone joint infect skin skin structur infect
loe ip expir
cantor expect steadi mid-single-digit sale eros driven primarili ex-u market
simponi golimumab once-monthli subcutan treatment certain inflammatori diseas rheumatoid arthriti
juvenila idiopath arthriti psoriat arthriti axial spondyloarthr ulcer coliti merck retain right simponi
throughout europ russia turkey per agreement johnson johnson cover profit
deriv merck distribut simponi equal divid merck
yoy declin includ unfavor effect foreign exchang reflect lower price
partial off-set higher volum europ
yoy growth includ favor effect foreign exchang driven eu volum
yoy growth includ favor effect foreign exchang driven eu volum
yoy growth includ favor effect foreign exchang primarili reflect higher eu
merck key immunolog product simponi remicad tnf-alpha inhibitor competitor product
class includ humira cimzia well approv biosimilar humira adalimumab remicad infliximab
cantor expect low-to-mid-single-digit sale eros gener humira
exhibit evaluatepharma outlook world-wide anti-tnfa mab market
remicad infliximab treatment inflammatori diseas rheumatoid arthriti crohn diseas pediatr crohn
diseas ulcer coliti pediatr ulcer coliti ankylos spondyl psoriat arthriti psorasi merck retain
right remicad throughout europ russia turkey per agreement profit deriv merck
distribut remicad equal divid merck
eu loe lost market exclus major eu market februari longer market exclus
yoy declin foreign exchang unfavor affect sale perform
yoy declin foreign exchang unfavor affect sale perform
exhibit ema approv biosimilar remicad
compani report cantor fitzgerald research
cantor expect continu price volum declin result biosimilar competit
samsung current ema-approv biosimilar approv follow indic ankylos spondyl crohn diseas psoriat arthriti psoriasi rheumatoid arthriti ulcer coliti prior remicad market outsid except japan certain asian market effect relinquish market right product certain territori retain exclus market right throughout europ russia turkey retain territori remicad sale declin reflect unfavor effect foreign exchang volum growth europ profit deriv distribut remicad equal divid merck complet acquisit hospira hospira enter agreement develop market certain biosimilar molecul celltrion includ inflectra exclus commerci right inflectra canada certain territori share inflectra commerci right celltrion europ collabor agreement manufactur commerci flixabi specifi eu countri began experienc biosimilar competit certain smaller eu market substanti sale declin came follow loss market exclus major eu market februari namemanufacturerd authorizationrevenu merck neurosci product belsomra
belsomra suvorex orexin receptor antagonist treatment insomnia orexin central promot
wake
loe loe novemb eu loe n/a japan loe
accord american academi sleep medicin treatment insomnia adult includ
restrict relax cognit behavior therapi
eszopiclon zaleplon temazepam flurazepam estazolam doxepin ramelteon suvorex
newer rx drug includ ramelteon rozerem suvorex belsomra
agent evid efficaci without specif fda indic insomnia benzodiazepin
receptor agonist specif indic insomnia treatment clonazepam lorazepam sedat
antidepress use alon combin benzodiazepin receptor agonist ramelteon
patient specif comorbid agent gabapentin tiagabin quetiapin olanzapin
avoid hypnot first-lin therapi chronic insomnia
cantor expect double-digit/high single-digit world-wide sale growth driven primarili
elig month pediatr exclus
merck compani report american academi sleep medicin access
isentress/isentress hd raltegravir hiv integras inhibitor use combin
antiretrovir agent treatment infect isentress twice-daili oral isentress hd
initi approv isentress hd approv
loe loe april eu loe japan loe
world-wide sale yoy declin primarili reflect lower demand eu
due competit pressur sale sale
world-wide sale yoy declin includ unfavor effect foreign
exchang driven primarili lower volum well lower demand price
eu due competit pressur partial off-set favor adjust discount reserv
 higher demand certain emerg market sale sale
world-wide sale yoy declin includ unfavor effect foreign
exchang driven primarili lower volum lower demand price eu
due competit pressur partial off-set higher volum latin america higher price
cantor expect continu sale declin driven continu competit pressur follow gener
eros eu/japan start
elig month pediatr exclus
zepati elbasvir grazoprevir fixed-dos combin product indic treatment chronic
hepat viru hcv genotyp gt infect adult ribavirin certain patient popul
loe ip expir may eu ip expir patent spc japan ip expir
global sale yoy declin includ unfavor foreign exchang impact driven
primarili unfavor effect increas competit declin patient volum particularli eu
japan juli announc price cut reduc out-of-pocket cost patient across countri
global sale yoy declin includ favor foreign exchang impact reflect
unfavor effect increas competit declin patient volum particularli
global sale yoy declin includ favor foreign exchang impact reflect
unfavor effect increas competit declin patient volum market particularli
think hepat market shrink overcrowd zepati attract product
patient combin product market includ
abbvi nc pan-genotyp treatment gt maviret glecaprevir pibrentasvir
gilead nc pan-genotyp treatment gt epclusa sofosbuvir velpatasvir
gilead harvoni ledipasvir sofosbuvir treatment gt infect
gilead pan-genotyp treatment gt vosevi sofosbuvir velpatasvir voxilaprevir
cantor expect continu signific sale declin due increas competit declin patient
elig month pediatr exclus
zetia ezetimib market ezetrol ex-u countri vytorin ezetimibe/simvastatin market inegi ex-
 atozet ezetimib atorvastatin market certain ex-u countri ezetimib famili
cholesterol modifi medicin lower ldl-c
loe zetia loe decemb eu loe april japan loe vytorin loe april eu loe
spc april japan loe
combin global sale yoy declin includ unfavor foreign exchang impact
driven primarili lower sale eu well declin partial off-set higher sale
japan due part launch atozet
combin global sale yoy declin includ favor foreign exchang impact
driven primarili declin sale reflect lower volum price zetia vytorin result gener
combin global sale yoy declin includ favor foreign exchang impact
driven primarili declin sale reflect lower volum price zetia vytorin result
gener competit partial off-set higher demand certain eu market japan
combin global sale yoy declin driven lower volum price zetia vytorin
 result gener competit
gener atozet launch franc itali ireland spain portug norway netherland
cantor expect zetia vytorin continu double-digit gener eros driven primarili eu
cantor expect atozet steadi single-digit growth
report zetia vytorin intern atozet figur round merck cardiovascular product adempa
adempa riociguat sgc soluabl guanyl cyclas stimul indic treatment
persistent/recurr chronic thromboembol pulmonari hypertens cteph group surgic treatment
inoper cteph improv exercis capac function class
pulmonari arteri hypertens pah group improv exercis capac improv function class delay
per collabor bayer cover merck lead commerci right adempa countri outsid america
bayer lead right america includ compani share profit equal merck began promot
distribut adempa europ transit bayer merck territori includ japan continu
exhibit summari adempa collabor bayer
merck compani report bayer annual report fda
germanyfranceitalyswitzerlandspainu chinajapanbrazilcanadau activ product patent term extens appli system japan allow patent extend provid later approv direct differ indic previou approv may result multipl approv given patent expir date patent applic pend elig month pediatr exclus februari
januvia sitagliptin janumet sitagliptin/metformin janumet xr sitagliptin/metformin extended-
releas fall dipeptidyl inhibitor class treatment type diabet
loe januvia loe juli eu loe japan loe janumet loe juli
eu loe japan loe n/a janumet xr loe juli eu loe n/a japan loe n/a
combin sale nearli yoy decreas includ unfavor effect foreign exchang
increas demand ex-u market off-set price pressur
combin sale yoy increas includ favor effect foreign exchang sale growth
reflect volum growth global partial off-set continu price pressur
combin sale yoy increas includ favor effect foreign exchang reflect
increas intern market driven higher demand partial off-set price pressur sale declin
reflect continu price pressur partial off-set volum growth well favor adjust rebat
combin sale yoy declin includ favor effect foreign exchang driven
primarili on-going price pressur partial off-set continu volum growth global
cantor expect mid-single-digit sale declin affect continu price pressur chang
medicar part coverag gap follow rapid gener eros lead
elig month pediatr exclus
system japan allow patent extend provid later approv direct differ indic previou approv may result multipl
approv given patent expir date
inhibitor work prevent breakdown reduc blood glucos level bodi inhibit
process break inhibitor allow remain activ bodi longer lower blood
glucos level elev inhibitor tend caus weight gain tend neutral
posit effect cholesterol level
accord edit american diabet associ ada standard medic diabet
combin therapi metformin prefer initi pharmacolog agent six prefer treatment
option inhibitor one
exhibit prefer combin therapi metformin type diabet
goal reduc blood glucos level minim side effect physician encourag adopt patient-
center approach decid agent use factor includ efficaci hypoglycemia risk histori atherosclerot
cardiovascular diseas impact weight potenti side effect renal effect deliveri method oral vs subcutan
cost patient prefer
typic goal mani nonpregn adult mmol/mol stringent goal mmol/mol
might suggest certain patient short durat diabet treat lifestyl metformin
long life expect signific cvd possibl without induc signific hypoglycemia
combin therapi inhibitor avail sulfonylureajanuvia sitagliptin thiazolidinedionetradjenta inhibitoronglyza inhibitornesina receptor agonistbas insulin janumet januvia metformin janumet xr janumet extended-releas merck diabet product januvia janumet janumet xr cont
cantor fitzgerald research edit american diabet associ ada standard medic diabet
note receptor agonist inhibitor prescrib combin situat may typic use combin inject therapi initi combin inject therapi metformin therapi maintain oral agent may discontinu individualbasi avoid unnecessarili complex costli regimen ad fourth antihyperglycem agent gener receptor agonist discontinu theiniti basal insulin sulfonylurea inhibitor receptor agonist typic stop complex insulin regimen beyond basal use diagnosi initi lifestyl manag set target initi pharmacolog therapi base monotherapi metformin unless contraind consid anoth agent consid dual therapyif blood glucos mg/dl patient markedli symptomat consid combin inject therapyif -assess medication-tak behavior-consid dual therapyify monitor everi monthsascvd ify add agent proven reduc major advers cv event and/or cv mortalityifno add second agent consider drug-specif effect patient target target month ify monitor everi target month ify monitor everi monthsifno -assess medication-tak behavior-consid combin inject therapyifno -assess medication-tak behavior-consid tripl therapi merck diabet product januvia janumet janumet xr cont
exhibit drug-specif patient factor consid select treatment
edit american diabet associ ada standard medic diabet
nuvar etonogestrel/ethinyl estradiol vagin ring estrogen/progestin combin hormon
contracept chc indic use women prevent pregnanc
loe ip expir april gener entri yet eu ip expir april japan ip n/a
world-wide sale yoy declin includ favor effect foreign
exchang driven primarili lower sale reflect lower volum partial
off-set higher price lower demand europ
world-wide sale yoy increas includ unfavor effect foreign
exchang larg reflect higher price volum declin europ partial off-set revenu
world-wide sale yoy increas includ unfavor effect foreign
exchang larg reflect higher price
cantor expect rapid gener eros begin potenti gener entrant includ teva neutral
mithra cover
implanon etonogestrel implant single-rod subderm contracept implant nexplanon etonogestrel
implant singl radiopaqu rod-shap subderm contracept implant nexplanon newer version
implanon radiopaqu seen x-ray ct scan ultrasound scan mri
make easier track physician follow insert
loe nexplanon ip expir septemb devic eu ip expir devic market
world-wide sale yoy increas primarili reflect higher price volum
growth
world-wide sale yoy increas includ unfavor effect foreign
exchang reflect higher demand partial off-set declin certain emerg market
particularli venezuela
world-wide sale yoy increas includ unfavor effect foreign
exchang driven primarili higher demand emerg market
cantor expect mid-single-digit sale growth prior
singulair montelukast sodium once-a-day oral medicin indic chronic treatment asthma
relief symptom allerg rhiniti merck longer market exclus singulair
loe loe august major eu market loe februari japan loe
world-wide sale yoy declin foreign exchang unfavor affect global sale
perform favor affect global sale perform sale
declin driven lower volum japan result gener competit
world-wide sale yoy declin includ favor effect foreign
exchang sale perform primarili reflect lower volum japan patent provid market
exclus singulair japan expir februari octob
world-wide sale yoy declin includ unfavor effect foreign
exchang sale declin driven primarili lower volum japan lower demand europ
result gener competit
cozaar losartan potassium companion agent hyzaar losartan potassium hydrochlorothiazid
treatment hypertens patent provid market exclus cozaar hyzaar
 major intern market expir also note major cozaar/hyzaar
sale come intern market oppos
loe cozaar hyzaar lost patent protect number major eu market start march
ip also expir
nasonex mometason furoat monohydr inhal nasal corticosteroid treatment nasal
loe pediatr exclus april howev gener apotex cover enter
 market march agreement gener manufactur abl launch gener version
nasonex eu market januari
global sale yoy declin driven substanti declin sale
result gener competit foreign exchang favor affect global sale perform
global sale yoy declin driven primarili lower volum
result gener competit also driven lower volum price europ on-going
gener eros lower sale venezuela due reduc oper compani countri
global sale yoy declin includ unfavor effect foreign
exchang declin driven primarili lower volum reflect competit altern
gener treatment option well suppli constraint addit lower volum price
europ on-going gener eros also contribut nasonex sale declin
arcoxia etoricoxib select inhibitor cyclooxygenas treatment arthriti
pain merck market outsid
initi approv n/a market outsid merck first launch ww april
follistim aq follitropin beta inject market puregon ou countri gonadotropin inject
use fertil treatment women men contain human follicle-stimul hormon hfsh
initi approv follistim aq formul approv
origin manufactur organon acquir schering-plough cover merg
merck novemb
loe ip expir formul expect august ip expir formul anticip
eu japan
global sale yoy declin color given
global sale yoy declin includ unfavor effect foreign exchang
primarili reflect lower volum europ due part suppli issu lower demand certain
global sale yoy declin reflect unfavor effect foreign exchang
off-set higher price
cantor expect continu double-digit sale declin driven lower demand
treatment prevent osteoporosi postmenopaus women
treatment increas bone mass men osteoporosi
treatment glucocorticoid-induc osteoporosi
treatment paget diseas bone
fosamax alendron sodium oral administr bisphosphon indic
dulera inhal aerosol mometason furoate/formoterol fumar dihydr combin oral
inhal medicin treatment asthma patient year contain corticosteroid
long-act beta agonist laba indic relief acut bronchospasm
 loe although patent expir combin expect may dulera
seen heavi price pressur sinc multipl substitut avail advair breo ellipta
global sale yoy declin driven lower sale reflect
on-going competit price pressur well lower demand
global sale yoy declin includ unfavor effect foreign
exchang driven lower sale reflect competit price pressur
partial off-set higher demand
global sale yoy growth driven primarili higher demand
cantor expect continu competit price pressur follow gener eros
merck anim health anim health divis merck anim health discov develop
manufactur market anim health product includ vaccin divis base new jersey
oper global network manufactur dedic facil commerci offic
countri busi oper countri merck anim health world second-largest
anim health compani sale larg anim health player includ zoeti overweight
previous part overweight elanco cover previous part overweight
merck anim health compani websit
merck remain consist list anim health key pillar long-term growth strategi say
see valu creation keep anim health busi separ busi merck
note merck anim health fastest-grow top-lin compani within anim health space
gener oper margin
accord compani meaning synergi anim health human health
would lost anim health separ anim health also high-margin high-growth
busi grow faster human health busi accord merck provid solid cash flow
use invest busi also provid diversif
think good exampl merck commit anim health announc
agreement compani acquir antelliq group privat compani focus digit
anim identif traceabl monitor solut euro ev/sal
anim health busi report sale livestock companion anim sale
categoriesproductsdescriptionnuflorantibiot rang use cattl swinebovilis/vista vaccin line infecti diseas cattlebanaminebovin swine anti-inflammatoryestrumatefor treatment fertil disord cattlematrixfertil manag swineresflorcombin broad-spectrum antibiot non-steroid anti-inflammatori drug bovin respiratori diseasezuprevofor bovin respiratori diseasezilmaxto improv product effici beef cattlesafe-guardde-worm cattlem pacswin pneumonia vaccineporcili circumventvaccin line infecti diseas swinenobilis/innovaxvaccin line poultryparacox coccivaccoccidiosi vaccinesexzolta system treatment poultri red mite infestationsbravectoa line oral topic product kill flea tick dog cat weeksnobivacvaccin line flexibl dog cat vaccinationotomax/mometamax/posatexear ointment acut chronic otitiscaninsulin/vetsulindiabet mellitu treatment dog catspanacur/safeguardbroad-spectrum anthelmint de-worm use mani animalsregumatefertil manag horsesprestigevaccin line horsesactivyl/scalibor/exspotfor protect bite flea tick mosquito sandfliessliceparasiticid sea lice salmonaquavac/norvaxvaccin bacteri viral diseas fishcompact pdvaccin salmonaquaflorantibiot farm-rais fishlivestock productspoultri productscompanion anim productsaquacultur product februari
global sale yoy increas includ unfavor effect foreign exchang
driven higher sale companion anim product primarili bravecto due part time
custom purchas delay flea tick season well higher sale livestock product
includ rumin poultri product
global sale yoy increas includ favor effect foreign exchang
driven higher sale companion anim product primarili bravecto due part delay flea
tick season time custom purchas well higher sale livestock product includ
rumin poultri swine product
global sale yoy increas includ favor effect foreign exchang
primarili reflect higher sale livestock product particularli rumin poultri product anim
sale growth also driven higher sale companion anim product driven larg
world-wide sale yoy increas primarili reflect higher sale companion anim
product larg driven growth bravecto reflect growth oral formul continu
uptak topic formul launch growth also driven higher sale
rumin poultri swine product
posit macro outlook anim health industri run overal growth rate support
durabl busi model
cantor expect mid-to-high single-digit growth driven primarili companion anim well livestock
merck compani report cantor fitzgerald research
report companion companion companion anim anim segment met criteria separ report becam report segment februari
merck co inc global healthcar compani deliv innov health solut prescript medicin vaccin
biolog therapi anim health product compani oper includ four oper segment anim health
allianc segment segment includ human health pharmaceut vaccin product
health pharmaceut product consist therapeut prevent agent gener sold prescript treatment
human disord anim health segment discov develop manufactur market anim health product includ vaccin
compani segment provid servic solut focu engag health analyt clinic servic
improv valu care deliv patient compani incorpor new jersey
